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ABSTRACT 
 
DEVELOPMENT OF A KINETIC MODEL TO INVESTIGATE THE EFFECT OF 
COMPOSITIONAL VARIATION AND A PROCESSING CONDITION ON THE  
SOLID-STATE DEGRADATION OF GABAPENTIN 
 
 
 
By 
Akshata A. Nevrekar 
August 2015 
 
Dissertation supervised by Ira S. Buckner, Ph.D. 
Gabapentin is used in the treatment of seizures and neuropathic pain.
  
Gabapentin 
undergoes intra-molecular cyclization to form a γ-lactam. The product lactam is twenty times 
more toxic than gabapentin, causing seizures in animal models. The United States Pharmacopeia 
(USP) limits the content of lactam in gabapentin formulations to 0.4% w/w. A number of patents 
have been issued for solid dosage forms formulated to stabilize gabapentin. Despite these efforts, 
factors contributing to gabapentin’s poor stability in the solid-state have not been explored 
completely. 
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It was hypothesized, that physicochemical properties of the excipients and compaction pressure 
will accelerate the solid-state degradation of gabapentin, increasing the kinetic rate constant for 
lactam formation. To test the hypotheses, binary mixtures and compacts of gabapentin with 
different excipients were prepared and stored under accelerated study conditions. The 
concentration of lactam and gabapentin was measured using a validated analytical method. A 
concentration dependent catalytic effect by the excipients was determined by mixing different 
concentrations of the excipient with gabapentin. The effect of excipient particle size was 
determined by mixing different size fractions of the excipient with gabapentin.  
 
Significant degradation of unprocessed gabapentin in the presence of excipients strongly 
suggested a catalytic role of the excipients on gabapentin’s degradation. The existing model was 
expanded to account for the observed catalytic effect of excipients. A relationship was developed 
between the rate constant for lactam formation and physical properties of the excipients (such as 
particle size, morphology, molecular weight, molecular cross sectional area and specific surface 
area). Along with the catalytic effect of the excipients, compaction pressure and powder 
properties of the excipients such as moisture content, particle size and yield pressure appeared to 
be other potential contributing factors affecting gabapentin’s degradation.  
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Chapter 1 
Introduction 
 
Solid-state degradation reactions occur commonly in drug substances and their formulations. 
These reactions occur due to a drug being intrinsically active or unstable.
1,2
 The degradation of 
drug molecules is typically accelerated by compositional factors, such as the presence of 
excipients, environmental conditions and exposure of drug molecules to processing conditions.
2
  
 
Excipients can potentially accelerate the degradation reaction by interacting chemically with 
drug molecules. An example of such an interaction would be acid-base reaction between an 
acidic drug and a basic excipient. Amorphous excipients, or excipients with greater non-
crystalline content, possess enhanced molecular mobility and ability to interact with water, 
resulting in accelerated drug degradation.
2,3
 Environmental conditions such as temperature and 
humidity can accelerate drug degradation by increasing kinetic energy and molecular mobility of 
the system.
2,4
 Environmental moisture can stabilize drug degradation by facilitating “self-
healing” of crystal defects induced during processing.5 Processing conditions involve energy 
input which induces changes in particle size, crystallinity, surface area and crystal form, resulting 
in modification of physical and chemical properties of a drug molecule.
6-11
 Application of stress 
on a drug crystal during processing creates lattice defects, which act as sites to initiate 
degradation reactions. These lattice defects can also contribute to lattice disorder, leading to 
different packing arrangements and conformations within a crystal, making conditions favorable 
for interaction.
2,12-14
 Hence, compositional, environmental and processing factors are critical in 
 
 
2 
 
determining the solid-state degradation of a drug and its dosage forms. Establishing drug stability 
and reactivity by taking the above factors into consideration becomes an  important criterion for 
designing a stable formulation, ascertaining shelf life, patient safety, storage conditions and 
optimizing manufacturing processes.
15
 The present research explores the underlying effects of 
compositional and processing factors affecting the solid-state degradation of the model drug 
gabapentin.  
 
1.1  Statement of Problem 
Gabapentin, [1-(amino methyl) cyclohexane acetic acid] is a γ-aminobutyric acid (GABA) 
analogue used in the treatment of epilepsy and neuropathic pain.
16,17
 It is also used in treatment 
of bipolar disorder and is effective in reducing spasticity associated with multiple sclerosis.
15
 The 
primary reason for its extensive commercial usage is milder side effects relative to older 
generation anti-epileptic agents.
18
  
Gabapentin undergoes degradation by nucleophilic attack of the alkyl amine on the carboxylate 
carbon to form γ-lactam [3, 3-petamethylene-4-butyrolactam] as shown in Figure 1.15 
                      
Figure 1: Intramolecular cyclization reaction for the conversion of gabapentin to lactam  
The degradation product, “lactam”, is known to be 20-times more toxic than gabapentin itself 
and has been reported to cause seizures in animal models.
19
 The United States Pharmacopeia 
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(USP) has recommended that the concentration of lactam in any gabapentin formulation should 
not exceed 0.4% w/w.
5
 Gabapentin is available commercially as either a tablet or a capsule 
dosage form each of which includes a number of different excipients. Hard gelatin capsules are 
available for a single dose, containing between 100-400 mg gabapentin, while elliptical film 
coated tablets are available for a single dose of 600-800 mg gabapentin.
20
 
 
In 2007, a voluntary recall of 73 million gabapentin tablets was announced by Ranbaxy 
Pharmaceuticals for exceeding the lactam impurity specifications of gabapentin formulations.
21
 
Thereafter, a number of patents have been filed to formulate a more stable dosage form 
containing gabapentin.
22-27
  
 
Literature findings
7,34
 have indicated that excipient type, pH conditions and buffering salt 
concentration may effect the degradation kinetics of gabapentin in solution. The possibility of a 
similar catalytic reaction (due to excipients, pH, salt concentration) in the solid-state, mediated 
by common excipients used to formulate gabapentin, requires further exploration. Hence, 
providing evidence for the role of excipient properties affecting the degradation of gabapentin 
needs to be attempted.  
 
Considering the commercial availability of gabapentin as tablets along with the excipients, the 
effect of compression pressure on the degradation kinetics needed investigation. Compaction as a 
processing condition could potentially increase the concentration of reactive molecules within 
gabapentin crystals, accelerating lactam formation. Therefore, the present reaserch will help 
 
 
4 
 
investigate the effect of excipient properties and compaction conditions affecting the solid-state 
degradation of gabapentin. 
1.2.  Hypothesis and Specific Aims 
Stemming from the previous research conducted on the solid-state degradation of gabapentin, the 
objective of this work was to develop an understanding of the role of excipients and 
compaction as a processing condition on the solid-state degradation of gabapentin. The 
research primarily focuses on determining the role of excipient concentration and their physical-
chemical properties on gabapentin’s degradation. The research will also help to identify other 
potential factors associated with powder properties of excipients and compaction conditions 
impacting gabapentin’s degradation. 
 The experiments were designed to test the central hypothesis, that physicochemical properties 
(such as specific surface area, molecular weight, particle size, particle shape and, acidic or 
basic strength) of the excipients will accelerate the solid-state degradation of gabapentin, 
increasing the rate constant (k2) for lactam formation. The degradation kinetics, 
predominantly the initial rate of lactam formation, will be further accelerated by 
compaction of the gabapentin-excipient physical mixtures. 
 
The overarching objective of the project is to use the research findings to develop a risk 
assessment tool, which would have the ability to predict the amount of lactam generated over a 
predetermined time frame in gabapentin formulations, in the presence of varying excipient 
properties and compaction conditions. 
 
 
 
5 
 
1.3. Literature Review 
1.3.1.  Model Compound Gabapentin 
Gabapentin is an achiral γ-amino acid, which has the propensity to undergo intramolecular 
cyclization to form a lactam molecule. The ability to undergo cyclization has been attributed to 
the close proximity between the amine and the carboxylic group in the gabapentin molecule.
28
 
 
Gabapentin was derived by adding a cyclohexyl group to the γ-amino butyric acid backbone.19 
Gabapentin is a white to off-white colored crystalline solid with a melting point of 165°C. It is 
freely soluble in water (~150 mg/ml at pH 7.4) under both acidic and basic conditions. It is a 
BCS class III drug with a log partition coefficient (n-octanol/0.05 M phosphate buffer pH 7.4) of 
-1.25.
20
 Gabapentin has a molecular weight of 171.24 g/mole, and pKa1 of 3.7 and pKa2 of 10.7 
respectively.
5
 It is a low potency drug and is typically dosed at high concentrations to provide the 
necessary pharmacological effect.
29
 The absorption of gabapentin in the brain is delayed because 
of its inability to passively diffuse the blood brain barrier (BBB).
19
 It is transported to the brain 
by saturable transporters.
19
 Gabapentin is toxic at concentrations of 8000 mg/kg. In the solid-
state, gabapentin exists in its zwitterionic form, while in solution, it exists as cationic, anionic, 
zwitterionic and neutral species depending on the pH of the solution.
30
 The lactam degradation 
product is a white crystalline solid with a melting point of 85°C.
83
 Lactam is toxic at a 
concentration of 300 mg/kg.
23
 
 
Pharmacology: Gabapentin is a GABA analogue that does not bind to GABA receptors or alter 
the metabolism of GABA in the brain. The binding sites for gabapentin are located on neurons in 
the brain that are rich in glutaminergic synapses. Gabapentin is also a weak inhibitor of the 
 
 
6 
 
branched chain aminotransferase enzyme involved in glutamic acid synthesis in the brain.
19
 The 
therapeutic action of the drug is thought to involve voltage gated calcium ion channels.
15
 Less 
than  3% of the administered drug is bound to the plasma proteins, and approximately 20% of the 
drug concentration is available for cerebrospinal fluid (CSF) circulation.
20
 Elimination of 
gabapentin from the systemic circulation occurs via renal excretion and the half-life in the body 
is between 5-7 h. 
20
 
 
1.3.2. Previous studies on gabapentin 
Physical Stability of gabapentin 
Four solid forms of gabapentin have been reported in the literature.
31
 The commercially available 
Form II is anhydrous, and is the most thermodynamically stable. Form I (monohydrate) is the 
most stable form in aqueous conditions, while Form III has a unique intramolecular hydrogen 
bond between the amine and the carboxylic groups. Form IV is hypothesized to be the last 
transformed polymorph of gabapentin before its intramolecular cyclization to the lactam 
molecule.
30,32,33
 
 
Progressive polymorphic transformation was observed upon heating gabapentin from ambient 
temperature to its melting temperature. It was observed that as gabapentin Form I is heated above 
its melting temperature it dehydrates and transforms to Form III followed by Form IV. In 
contrast, heating Form II and Form III under similar conditions, results in direct transformation 
to both Form IV with some degradation to lactam.
32
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Commercially available Form II is physically stable in up to 50% RH conditions while Form III 
and Form IV transform to Form II under similar humidity conditions. At 100% RH conditions all 
the anhydrous Forms (Form II, III, and IV) of gabapentin transform to the monohydrate.  
 
Grinding and kneading results in polymorphic conversion of gabapentin Form III and Form IV to 
Form II, however gabapentin Form II remains physically stable under these conditions. Form I, 
on the other hand, undergoes transformation to Form III at elevated temperatures (50°C) and 
Form IV under desiccated conditions.
21
 The above results indicate the physical stability of 
gabapentin Form II (used in the presented research) under the accelerated environmental 
conditions (50°C / 5% RH) and the physical mixing used in the presented research. 
 
Inter-conversion between polymorphic forms of gabapentin has been observed when it is 
exposed to processing conditions such as milling (ball mill), and accelerated temperature 
conditions (50°C) in the presence of excipients. It was observed that co-milling gabapentin for 
120 min along with excipients, (such as calcium phosphate dihydrate, magnesium stearate, 
cyclodextrins, mannitol and corn starch), did not cause any polymorphic transformation of the 
stable Form II, while co-milling with excipients, (such as microcrystalline cellulose, 
hydroxypropylmethylcellulose (HPMC) and Kollidon
®
 K-30), demonstrated polymorphic 
transformation from Form II to Form IV. Co-milling gabapentin with fumed silicon dioxide and 
talc resulted in conversion of Form II to Form IV and a significant amount of lactam. The 
polymorphic conversion of gabapentin was thought to be induced by co-processing gabapentin 
with excipients.
7
 The type of excipient processed with gabapentin seemed to affect the 
transformation. The energy used in co-milling the materials increased the mobility of gabapentin 
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molecules to facilitate form change. Additionally, the nature (hard/soft) of excipients co-milled 
with gabapentin contributed to the increased molecular mobility and accelerated form 
conversion. It is important to note the potential role of excipient type in driving the polymorphic 
conversion of processed gabapentin. The findings of the above study are especially important 
when determining the effect of excipient type especially its nature on the solid-state degradation 
of compacted gabapentin in the presented research. 
 
Chemical Instability of Gabapentin in Solution State 
Gabapentin was found to be unstable in aqueous solution and capable of undergoing cyclization 
to  form the lactam degradant.
7,34
 Heating a buffered solution (0.025-0.1M) of gabapentin at  
80°C resulted in accelerated lactam formation (Figure 2). A plateau of maximum reaction rate 
for lactam formation was reached when the amine was present as a free base (nucleophile). A  
27-fold decrease in the reaction rate was observed after increasing the amount of protonated 
amine. The pH-rate profile for the reaction showed a minimum degradation rate at neutral pH 
conditions (pH 6-7)  and significant reactivity at both acidic pH (pH 2.2) and basic pH conditions  
(pH >10) 
7,34
.  
 
A scheme for lactam formation in solution under different pH conditions was proposed in  
Figure 3. In this scheme, the neutral amino group acts as a nucleophile, attacking the 
deprotonated carboxyl carbon, to drive lactam formation. The zwitterionic and the cationic forms 
of gabapentin on the other hand are relatively less reactive.
34
 The observed reactivity at low pH 
was thought to be due to the attack of the free amino group on the protonated carboxyl group, 
leading to formation of a neutral tetrahedral intermediate (T
0
) as seen in Figure 3. General acid 
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catalysis resulted in breakdown of the intermediate form by addition of a proton provided by the 
buffering species to the leaving hydroxyl group.  
 
The kinetics for lactam formation were observed to be dependent on buffer concentration 
(general base catalysis), buffer type (sulfate, acetate, phosphate, and borate) and pH conditions. 
The lactam formation was catalyzed (specific base catalysis) under both acidic and basic pH 
conditions.
15
 This solution state degradation of gabapentin catalyzed by the above mentioned 
factors was further accelerated by increasing temperature conditions.
32,35,36
 
 
Figure 2: Solution state degradation of gabapentin under different pH conditions.
15
 An 
accelerated lactam formation was observed under both acidic and basic pH conditions. 
“Reprinted from Tetrahedron, volume 64, issue 28, Zambon Elena, Giovanetti Roberto, Cotarca 
Livius, Pasquato Lucia. Mechanistic investigation on 2-aza-spiro[4,5]decan-3-one formation 
from 1-(aminomethyl)cyclohexylacetic acid (gabapentin), pp 6739-6743, Copyright (2008), with 
permission from Elsevier.” 
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Figure 3: Mechanism for the degradation of gabapentin in solution.
15
 The zwitterionic form 
(B) and the protonated form (A) are less reactive than the unprotonated form (C). 
“Reprinted from Tetrahedron, volume 64, issue 28, Zambon Elena, Giovanetti Roberto, Cotarca 
Livius, Pasquato Lucia. Mechanistic investigation on 2-aza-spiro[4,5]decan-3-one formation 
from 1-(aminomethyl)cyclohexylacetic acid (gabapentin). pp 6739-6743, Copyright (2008), with 
permission from Elsevier.” 
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Chemical Instability of Gabapentin in the Solid-State 
Gabapentin was found to be susceptible to milling-induced chemical instability. This instability 
was attributed mainly to the formation of crystal defects, which increased the concentration of 
reactive gabapentin molecules. These reactive molecules, primarily comprising of the surface 
molecules and other damaged molecules in the bulk of the crystal, were capable of 
spontaneously converting to lactam at a faster rate compared to the less reactive molecules 
(stable) in the bulk of the crystal.
5
 The increased rate (500-fold) of lactam formation on milling 
was credited to the combined effects of enlarged surface area, duration of milling and in-process 
lactam levels.
1,5
  
 
The presence of environmental moisture was seen to stabilize milled gabapentin by enabling 
healing of crystal defects incorporated during milling.
5
 Healing of crystal defects was further 
expedited by surface adsorbed moisture.
5
 Milled gabapentin particles demonstrated higher 
stability when stored under relative humidity conditions greater than 31%. 
 
Conversion of lactam back to gabapentin, was found to be irreversible under varying conditions 
of humidity (31-81% RH), temperature (50°C, and 80°C) and in buffered solutions  
(pH 2.2, 7.0, 8.5).
5 
These results highlighted that conversion of lactam back to gabapentin only 
occurs under harsh conditions and is less likely to occur under the accelerated study conditions 
used in our research to test gabapentin’s stability. However, the role of excipient moisture on the 
degradation of gabapentin needs to be further studied considering, the ability of moisture to 
either stabilize gabapentin or potentially accelerate the catalytic effect of the excipients. 
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Solid-State Stability of Gabapentin Co-Processed with Excipients 
 A study investigated lactam formation in lyophilized blends of gabapentin with cyclodextrins, 
lactose, polyvinyl pyrrolidone (Kollidon
®
 K-30), mannitol, trehalose and D-raffinose.
37
 The 
mixtures were maintained at 50°C and variable humidity conditions (0, 45, 75% RH). 
Accelerated lactam formation was not observed when gabapentin in its freeze dried form was 
maintained under accelerated temperature and humidity conditions in the absence of excipients. 
Amongst the excipients lyophilized with gabapentin, highest lactam formation was observed in 
mixtures of gabapentin with cyclodextrins, especially HP-β-cyclodextrin. The accelerated 
lactamization was attributed to the restricted conformational freedom between the reacting 
functional groups of gabapentin as a result of inclusion complexation. Increasing humidity was 
seen to further accelerate lactam formation, due to moisture facilitating inclusion of gabapentin 
in the cavity of cyclodextrin. Accelerated lactam formation was observed in case of lyophilized 
blends of gabapentin with Kollidon
®
 K-30 and lactose. A possible explanation for the effect of 
lactose was thought to involve Maillard reaction and successive Amadori rearrangement between 
lactose and the primary amino group of gabapentin. However, lyophilized mixtures of 
gabapentin and sugars did not show accelerated lactam formation. The study however speculated 
reasons for the effect of excipient type but was not able to clearly separate the effect of excipient 
properties from other convoluting effects of lyophillization.
37
 The presented research will further 
explore the effect of excipient properties affecting the kinetics of lactam formation in the absence 
of any processing conditions. 
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Kinetic Model for Solid-State Degradation of Gabapentin 
A quantitative solid-state kinetic model (Figure 4) has been developed, that accounts for the 
mechanistic effects of environmental conditions and processing conditions (milling) on the 
degradation of gabapentin.
1
 The degradation was successfully described by rate constants k1  
(h
-1
mol
-1
) for autocatalytic branching, k2 (h
-1
) for spontaneous dehydration, k3 (h
-1
mol
-1
) for 
moisture induced recovery or branching termination and gaba0
*
 (% mole), which represented 
chemically intact gabapentin molecules with greater reactivity or mobility present inherently in 
the crystal. The kinetic model assumes formation of lactam by spontaneous conversion of gaba
*
.
1
 
Equations 1-3 describe the kinetics for the solid-state degradation of gabapentin.
1
 
 
 
Figure 4: Kinetic scheme describing solid-state degradation of milled gabapentin stored 
under accelerated temperature and humidity conditions.
1
 “(Kinetic Model for Solid-State 
Degradation of Gabapentin. J. Pharm. Sci., Vol. 101, pp 2123-2133), by Zong. Z., Qui. J., 
Tinmanee. R., Kirsch. L.E. Copyright (2012) by Wiley periodicals, Inc.. Reproduced with 
permission from Wiley periodicals, Inc. via Copyright Clearance Center.” 
 
𝐝[𝐠𝐚𝐛𝐚]
𝐝𝐭
= −𝒌𝟏 [𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂
∗ + 𝑳] + 𝒌𝟑[𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂
∗] 
Equation 1   
𝐝[𝒈𝒂𝒃𝒂∗]
𝐝𝐭
= 𝒌𝟏[𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂
∗ + 𝑳] − 𝒌𝟑[𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂
∗] − 𝒌𝟐[𝒈𝒂𝒃𝒂
∗] 
Equation 2 
𝐝[𝐋]
𝐝𝐭
= 𝒌𝟐[𝒈𝒂𝒃𝒂
∗] 
Equation 3   
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A typical degradation profile for milled gabapentin under accelerated environmental conditions 
(40°C / 5% RH) was described by two predominant phases (Figure 5). The first phase ((1) Figure 
5) primarily involved the initial lactam formation due to rapid conversion of the reactive 
gabapentin molecules inherently present in the sample (gaba0
*
). This was followed by the second 
phase ((2) Figure 5), described by a combination of disorder propagation, moisture induced 
termination and chemical conversion of gabapentin to lactam.
1 
The model involved consecutive 
processes of crystal defect propagation and spontaneous conversion of gabapentin to lactam. The 
kinetics for gaba
*
 formation were described as an autocatalytic process with the rate being 
catalyzed by the concentration of gaba
*
 and lactam.  
 
 
 
 
 
 
 
 
Figure 5: Degradation profile for milled gabapentin under accelerated storage conditions. 
The degradation profile on the left of the dotted line (1) denotes the initial rate of lactam 
formation predominantly described by rate constant k2 and gaba0
*
.
 
The degradation profile 
on the right of the dotted line (2) is predominantly described by rate constants k1 and k3. 
This phase represents the autocatalytic branching or moisture induced termination phase 
in the degradation kinetics. “(Kinetic Model for Solid-State Degradation of Gabapentin. J. 
Pharm. Sci., Vol. 101, pp 2123-2133), by Zong. Z., Qui. J., Tinmanee. R., Kirsch. L.E. 
Copyright (2012) by Wiley periodicals, Inc.. Reproduced with permission from Wiley 
periodicals, Inc. via Copyright Clearance Center.” 
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In summary, the cyclization reaction is believed to initiate at imperfection sites within the crystal 
lattice. As the concentration of reactive gabapentin molecules is consumed, the reaction 
propagates due to the generation of new nuclei at lactam and gabapentin molecular interfaces. 
Environmental temperature conditions impact rate constants k1, k2, k3, while moisture conditions 
have a predominant effect on rate constant k3. Extended Arrhenius equation (Equation 4-6)
1 
 was 
used to estimate the rate constants for gabapentin’s degradation after milling as a function of 
environmental conditions in the absence of excipients.
1
 
𝒌𝟏 = 𝟏. 𝟒𝟖 × 𝟏𝟎
𝟏𝟎 × 𝐞𝐱𝐩 (−
𝟏𝟎𝟕𝟎𝟕
𝑻
) Equation 4 
𝒌𝟐 = 𝟐. 𝟒𝟎 × 𝟏𝟎
𝟗 × 𝐞𝐱𝐩 (−
𝟖𝟐𝟗𝟓
𝑻
) Equation 5 
𝒌𝟑 = 𝟐. 𝟏𝟓 × 𝟏𝟎
𝟔 × 𝐞𝐱𝐩 (−
𝟖𝟏𝟔𝟑
𝑻
) × 𝐞𝐱𝐩(𝟎. 𝟎𝟗𝟐𝟑 × % 𝑹𝑯) Equation 6 
Milling duration impacted the value of gaba0
*
, which was estimated to vary between  
0.46-1.04% mole for gabapentin samples milled between 15-60 min.
1
 The study clearly 
demonstrated that the processing increased the concentration of reactive gabapentin molecules. 
 
The above equations can be used to estimate the value of  rate constants and the concentration of 
reactive gabapentin molecules after processing and varying the environmental conditions. In the 
presented research, the estimates would be used to establish a range for the initial parameter 
values during parameterization of the data, using non-linear regression.  
 
1.3.3. Commonly Used Pharmaceutical Excipients 
The chemical structures or formulae for all the excipients procured in the study are provided in 
Table 1. 
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    Table 1: Structural Information for the Excipients used in the Study
38
 
Excipient chemical name Common name Structure / chemical formula 
Dibasic calcium phosphate 
dihydrate 
Emcompress
®
 Ca(HPO4)·2H2O 
Dibasic calcium phosphate 
anhydrous 
A-Tab
®
 Ca(HPO4) 
Tribasic calcium 
phosphate 
Tri-Tab
®
 Ca5OH(PO4)3/10CaO3P2O5·H2O 
Monobasic calcium 
phosphate 
Mono-Tab Ca(H2PO4)2 
Starch Unipure
®
 DW 
 
HPC Klucel
®
 EF 
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HPMC Methocel
®
 
 
Magnesium silicate Talc  
 
Dibasic calcium phosphate anhydrous (A-Tab
®
) and Dibasic calcium phosphate dihydrate 
(Emcompress
®
)  
 
The major pharmaceutical application of dicalcium phosphate is that of a diluent in tablet and 
capsule formulation due to its good compaction and flow properties. Its predominant 
deformation mechanism is by brittle fracture. The molecular weight of A-Tab
®
 is 136.06 g/mole 
and that of Emcompress
® 
is 172.09 g/mole. Dicalcium phosphate is non-hygroscopic and is 
stable at room temperature. The anhydrous grade does not transform to the dihydrate form. 
However, the dihydrate form can lose its water of crystallization under high temperature and low 
humidity conditions. The true density of the anhydrous grade of dicalcium phosphate is around  
2.89 g/cm
3
, while bulk and tap densities are 0.78 g/cm
3
 and 0.82 g/cm
3
 respectively. The true 
density of the dihydrate form is 2.38 g/cm
3
 and bulk and tap densities are 0.91 g/cm
3
 and 1.17 
g/cm
3
 respectively. The average particle size diameter is around 180 μm for both the anhydrous 
and the dihydrate form. The specific surface area (20-30 m
2
/g) for the anhydrous form is greater 
relative to the specific surface area (0.44-0.46 m
2
/g) for the dihydrate form. The excipient is 
known to be incompatible with tetracycline antibiotics and drugs such as indomethacin, aspirin, 
aspartame, ampicillin, cephalexin, and erythromycin.
38
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Tribasic Calcium Phosphate (Tri-Tab
®
) 
Tri-Tab
®
 is used in the pharmaceutical industry as an anti-caking agent, glidant, diluent and 
binder in case of direct compression or wet granulated formulations. In some cases, the excipient 
is also used as a tablet disintegrant and as a major source of calcium and phosphorus. Its primary 
bonding mechanism is by plastic deformation.
38
 
Tribasic calcium phosphate is available in two forms 1. Ca(PO4)2 with a molecular weight of 
310.20 g/mole and 2. Ca5(OH)(PO4)3 with a molecular weight of 1004.70 g/mole. In the 
dissertation studies, the second form of Tri-Tab
®
 was used. The true density of the material is 
3.14 g/cm
3
 while, bulk and tap density values are 0.3-0.8 g/cm
3
 (powder form-granular form) and 
0.95 g/cm
3
 respectively. The melting point is 1670°C, providing stability to the material under 
high temperature conditions.  Specific surface area of the material is 70-80 m
2
/g. The material is 
slightly hygroscopic (2% moisture content, under 15-65% RH conditions) as the surface 
moisture is picked up and contained within small pores in the crystal structure. The excipient is 
available with an average particle diameter of 350 μm and is known to be incompatible with 
tetracycline antibiotics and tocopheryl acetate.
38
 
 
Hydroxypropyl Cellulose (HPC/Klucel
®
) 
Hydroxypropyl cellulose (HPC/Klucel
®
) is partially substituted poly (hydroxypropyl) ether of 
cellulose, containing not more than 0.6% silica or other anticaking agent. The excipient is used in 
the pharmaceutical industry as a coating agent for extended release formulations, binding agent, 
stabilizing agent, emulsifying agent and viscosity enhancing agent. 
The molecular weight is dependent on the chain length and varies between  
50,000-12, 50,000 g/mole. The material has a bulk density of 0.5 g/cm
3
 and a glass transition 
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temperature of 130 °C. The material decomposes between 260-275°C.  The material is slightly 
hygroscopic adsorbing about 4% w/w moisture at 50% RH conditions and 12% w/w moisture at 
84% RH conditions. The material is known to be incompatible with substituted phenol 
derivatives, methyl and propyl paraben.
38
 
 
Hydroxypropyl Methyl Cellulose (HPMC, Methocel
®
) 
Hydroxypropyl methyl cellulose is used in the pharmaceutical industry as a bio-adhesive 
material, coating agent in controlled release formulations, dissolution enhancing agent, 
emulsifying agent, dispersing agent, film forming agent and in extended and modified release 
formulations. It is available as several grades varying in their molecular weight between  
10,000-15,00,000 g/mole and one to two degrees of substitution. The degree of substitution 
denotes the amount of substituent groups on the anhydroglucose units of cellulose. True density 
of the material is 1.32 g/cm
3
 and bulk and tap density are 0.34 g/cm
3
 and 0.55 g/cm
3 
respectively. 
Glass transition temperature of HPMC is between 170-180°C, and it decomposes at 
approximately 230 °C. It is slightly hygroscopic and absorbs ~10% moisture at relative humidity 
conditions of 70%. HPMC is known to be incompatible with oxidizing agents, and is known to 
form a complex with metallic salts or ionic organics to form insoluble precipitates.
38
 
 
Pregelatinized Starch 
Pregelatinized starch (Unipure
®
) is chemically or mechanically processed to rupture all or parts 
of the starch granules. Partial gelatinization renders starch flowable and directly compressible, 
while full gelatinization produces cold water soluble starch which is mainly used as a wet 
granulating agent. Pregelatinized starch, is known to contain 5% free amylose, 15% free 
amylopectin and 80% unmodified starch. It is used in the pharmaceutical industry as tablet or 
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capsule diluent, disintegrant and tablet binder. In comparison to starch, pre-gelatinized starch 
possesses enhanced flow properties and compression characteristics. The material deforms 
predominantly by plastic flow accompanied by substantial elastic deformation.
38
 The true density 
of pre-gelatinized starch is 1.51 g/cm
3
 and bulk and tap densities are approximately  
0.58 g/cm
3
 and 0.87 g/cm
3
 respectively. Pre-gelatinized starch is hygroscopic and absorbs 
approximately 15% w/w moisture at 70% RH conditions. Mean particle diameter is around  
52 μm and specific surface area varies between 0.18-0.28 m2/g.38 
 
Talc  
Talc is purified, hydrated magnesium silicate with a molecular formula of Mg(Si2O5)4(OH)4. It 
may contain variable amounts of iron and aluminium silicate as impurities. It is used in the 
pharmaceutical industry as an anticaking agent, glidant, tablet and capsule diluent, lubricant and 
dissolution retardant in controlled release formulations. Talc adsorbs insignificant amounts of 
moisture at 90% RH conditions and ambient temperature conditions. Almost 99% of talc 
particles pass through sieve number 44 (355 µm) and have a specific surface area of  
2.41-2.42 m
2
/g. Talc is known to be incompatible with quartenary ammonium compounds.
38
 
 
Monobasic Calcium Phosphate 
Monobasic calcium phosphate is used in the food industry as a leavening agent and in the 
pharmaceutical industry for tablet production, due to its desirable flowability and good 
compaction properties. The material is of anhydrous grade, white in color, granular and free 
flowing. It is non-hygroscopic with true density of 2.23 g/cm
3
 and has poor water solubility  
(18 g/l). Monobasic calcium phosphate is a considerably strong acid with a pH value of 2 for its 
25% w/v slurry. The majority (95% w/w) of its particles pass through sieve of mesh size 90 µm. 
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The acidic nature of the excipient limits its usage with drugs prone to acid catalyzed 
degradation.
38,39
 
Based on the above information, all excipients used in the presented research are likely to be 
both physically and chemically stable under the accelerated study conditions employed. Most of 
the excipients are also not likely to absorb large quantities of water under the low humidity 
conditions (5%) of the study. Thus the confounding effect of moisture on gabapentin’s stability 
during the accelerated storage period is less likely. 
 
1.3.4. Models and Complexities in Solid-State Kinetics   
The kinetic model for gabapentin reported in the literature included critical mechanisms such as 
nucleation of lactam molecules in gabapentin crystals and autocatalysis of the conversion of 
stable gabapentin molecules to reactive gabapentin molecules. The kinetic model designed to 
predict solid-state stability of gabapentin has a combination of nucleation model theory and 
Prout-Tompkins autocatalytic theory. Therefore it is important to understand the mechanisms 
and principles underlying the existing solid-state models reported in the literature.  
 
Solid-state kinetics differs from a typical solution state reaction due to the inhomogeneity 
associated with the solid sample. The reactivity is different across different regions in the solid, 
depending on the molecular degrees of freedom across the solid sample. In solids, reactions are 
typically initiated at defect sites in the crystal lattice or at crystal surfaces, edges and corners. 
Ideally, a perfect crystal has minimal reactivity due to the absence of any imperfections. 
However, perfect crystals are rare and most crystal lattices contain imperfections. The lattice 
imperfections are predominantly in the form of point defects and dislocations. The imperfection 
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sites are energized sites due to molecules possessing higher free energy, resulting in lower 
activation energy required to initiate and drive the reaction.
40
  
 
A kinetic model is a theoretical and/or a mathematical description of a kinetic event that occurs 
experimentally. In solid-state, a model can describe a particular reaction type and translate that 
mathematically into a rate equation. Based on the mechanistic assumptions of the model and the 
shape of the isothermal plot of concentration vs. time, they can be classified as sigmoidal, 
acceleratory, linear or deceleratory.
40, 41
 
 
Nucleation Model Theory: The kinetics of many solid-state reactions are described by 
nucleation models typically the Avrami model. The rate limiting step in the model is assumed to 
be the formation and growth of nuclei, which are finite quantities of products in the reactant 
lattice. Nucleation models account for both nucleation and growth rates. However, the energy 
barrier for nuclei generation would be larger relative to that for growth. The contribution of 
nucleation may decrease as the reaction progresses, leading to an effective activation energy 
that varies with the progress of the reaction. Nucleation rates are derived based on the 
assumption that nucleation is either single step or involves multiple steps. Single step nucleation 
assumes that nucleation and growth both take place in a single step, while in multi-step 
nucleation, several steps are required to generate a growth nucleus.
40,42-44
 In the presented 
research, the spontaneous conversion of reactive gabapentin to lactam is assumed to follow a 
single step nucleation reaction. 
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Reaction Order Based Model Theory: The rate law is based on the reaction order. These 
models are simple models similar to those used in homogenous kinetics. In these models, the 
reaction rate is proportional to the concentration, the amount or fraction, of remaining reactant 
raised to a particular power. This is the reaction order.
40-42, 45
 
 
Autocatalytic Model Theory: In homogenous kinetics, autocatalysis will occur when the 
products catalyze the reaction. This occurs when the reactants are regenerated in the process 
known as branching. In autocatalytic models, the reaction rate increases as the products are 
formed. The reactants will be consumed over time and the reaction will enter the termination 
stage where it will cease. The reaction rate vs. time profile shows a bell shaped plot with both 
an acceleration and a decay period. The model was first derived by Prout and Tompkins for 
thermal decomposition of potassium permanganate which produced considerable crystal 
cracking during decomposition. The mechanistic model of nucleus branching was used to 
formulate the Prout-Tompkins model.
46-48
 In the presented research, the generation of reactive 
gabapentin molecules within a particle of gabapentin is expected to be autocatalyzed by the 
concentration of lactam and inherent reactive molecules. 
 
The Prout –Tompkins equation involves three assumptions:  
1. Linear dependence of the termination rate constant (kT) on the concentration of the reactant 
species. 2.  If the first assumption holds valid then kT = kb/2ai where a = ai at inflection point on 
the curve and kb is the branching rate constant. 3.  Value of  ai = 0.5 requires a sigmoidal curve 
function. The derivative form of the Prout-Tompkins model is provided in Equation 7. 
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𝒅𝒙
𝒅𝒕
=  𝒌′ (𝟏 − 𝒙)(𝒙) Equation 7 
In the above equation, x denotes the mole fraction of the product measured at time t, and k’ 
(mol
-1
h
-1
) is the rate constant for the transformation.
46
 
 
Major complexities in solid-state kinetics of drug molecules 
Solid-state kinetics typically involves major complexities, which need to be understood in order 
to define the model assumptions. Some of the complexities relevant to the presented research 
have been discussed below. 
 
Distribution of reactive molecules: different samples of a material can possess different 
concentrations of defect sites, defect types, and concentration of reactive molecules. Since the 
above molecules are more reactive than ordered bulk molecules, they undergo a reaction at 
different rates creating a complex kinetic scheme for drug degradation. This complexity exists 
in the case of gabapentin’s degradation, wherein reactive molecules are likely to have different 
rates of degradation and varying degrees of freedom. When describing degradation using a 
kinetic scheme, it is important to describe it with simplicity in order to be able to accurately 
estimate rate constants involved in the degradation. In the presented research, it is assumed that 
no major differences are present between the degradation rates of disordered molecules due to 
differences in their defect type (either on the surface or in the bulk of the crystal). In summary, 
all the disordered molecules in the gabapentin crystal are assumed to have similar reactivity 
irrespective of their defect type.   
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Particle size variations in the sample: for reactions initiating at imperfection sites or crystal 
surfaces, larger particles with lower specific surface area will likely have a lower overall rate of 
degradation relative to smaller particles. Samples with variable particle sizes have a potential to 
show complex reaction behavior. To eliminate the issue associated with varying particle size 
distribution in the sample, gabapentin and the excipients selected for the presented research 
were controlled for their particle size fractions. 
 
Powder packing: sample packing could affect solid reaction kinetics, wherein loosely packed 
powders, containing air pockets can have variable reaction kinetics compared to a tightly 
packed sample. This is due to the reduced thermal conductivity of the air pockets in loose 
powder or their ability to trap evolved gases.
40,41
 This could be one of the complexities 
especially seen in the case of compacts of physical mixtures of gabapentin with the excipients. 
The presented research, will explore the relationship between compact porosity of gabapentin-
excipient physical mixture and the initial rate for lactam formation. 
 
All the above complexities need to be considered when analyzing the kinetic data and selecting 
a model for the solid-state drug degradation. Therefore understanding the mechanism of 
degradation is critical when defining solid-state kinetics of drug molecules.  
 
1.3.5. Solving Ordinary Differential Equation and Non-Linear Regression 
On application of the desired model, the differential equations associated with the model need 
to be numerically treated for approximation of a solution and estimation of the kinetic 
parameters. The initial value problem for a differential equation involves finding a function y(t) 
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that satisfies the initial condition y(t0) =  y0 A numerical solution based on equation 8 
generates a sequence of values for every independent variable, t0, t1, ,….. tn, and a corresponding 
sequence of values for the dependent variable y0, y1, ……, such that each yn approximates the 
solution at tn.. Determination of step size (hn) is important when approximating a solution using 
numerical methods (Equation 9). 
𝒅𝒚
𝒅𝒕
= 𝒇(𝒕, 𝒚(𝒕)) 
Equation 8 
𝒉𝒏 =  𝒕𝒏+𝟏 − 𝒕𝒏 Equation 9 
The simplest numerical method for solution of an initial value problem is Euler’s method. It uses 
a fixed step size h and generates an approximate solution by using Equation 10 and Equation 11 
𝒚𝒏+𝟏 =  𝒚𝒏 + 𝒉𝒇(𝒕𝒏, 𝒚𝒏) Equation 10 
𝒕𝒏+𝟏 =  𝒕𝒏 + 𝒉 Equation 11 
The biggest defect of the Euler’s method is that it does not provide an error estimate. 
Single step methods are often called Runge-Kutta methods, after the two German 
mathematicians. The classical Runge-Kutta was used for hand computations before the 
invention of digital computers. It uses four function evaluations per step as shown in a series of 
equations (Equation 12-16).
49,50
 
𝒔𝟏 = 𝒇(𝒕𝒏, 𝒚𝒏) Equation 12 
𝒔𝟐 = 𝒇 (𝒕𝒏 +
𝒉
𝟐
 𝒚𝒏 +  
𝒉
𝟐
 𝒔𝟏) Equation 13 
𝒔𝟑 = 𝒇(𝒕𝒏 +
𝒉
𝟐
 𝒚𝒏 +  
𝒉
𝟐
 𝒔𝟐) Equation 14 
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𝒔𝟒 = 𝒇(𝒕𝒏 + 𝒉 𝒚𝒏 + 𝒉 𝒔𝟑) Equation 15 
𝒚𝒏+𝟏 =  𝒚𝒏 +  
𝒉
𝟔
 (𝒔𝟏 + 𝟐𝒔𝟐 + 𝟑𝒔𝟑 + 𝒔𝟒) Equation 16 
After numerically estimating the solution to the differential equations using initial value 
estimates for the parameters, the next step is to use non-linear regression to optimize parameter 
estimations, which will provide a predicted curve that best fit the data.  
Non-Linear Regression 
A number of data sets are analyzed by fitting a curve using non-linear regression. Curve-fitting 
standardizes data interpretation into a uniformly recognized form. Curve-fitting describes 
experimental data as a mathematical equation in the form y = f(x), where x is the independent 
variable and y is the dependent variable, and f is the function including the  parameters that 
describe the data.
51
 
 
The non-linear regression is a powerful tool for fitting an equation to a set of data in order to 
acquire values of unknown parameters. Similar to linear regression, non-linear regression 
procedures determine parameter estimates by reducing the sum of squares of the distances of the 
data points to the curve (least squares approach). If the ‘y’ value of each observed data point is 
called ydata and the y predicted value of the curve is called ycurve, the goal is to minimize the 
residual sum of squares (SS) as calculated in Equation 17. These methods are appropriate when 
the experimental uncertainty is Gaussian and unrelated to the values of x and y.
52
 
 𝑺𝑺 = 𝒔𝒖𝒎 [(ydata – ycurve)
2
]   Equation 17 
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The non-linear regression problems are solved iteratively. An initial estimate of the value for 
each parameter is provided; the non-linear regression procedure then adjusts these values to 
improve the fit of the curve to the data. The iterations (value adjustments) continue until 
negligible improvement of the fit is observed. All iterative techniques are given a starting point 
or initial estimate of parameter values by calculation or intelligent guessing. Several methods can 
be chosen to perform the iterations. One of the commonly used techniques is the Marquardt 
method. This method involves a combination of two algorithms namely, the method of steepest 
descent and Gauss-Newton.
52
 
 
The method of steepest descent works by providing an arbitrary step length to move along the 
direction of steepest descent. This procedure is then repeated until the lowest value for the sum 
of squares is obtained. Essentially, a minimum sum of squares is obtained by moving downhill 
from the initial estimates provided for the parameters.
52
 
 
The Gauss-Newton algorithm alters the value of parameters to directly reach the minimum The 
Gauss-Newton method works poorly with initial iterations, and may result in a poor fit or a 
wrong solution. This method works well when the sum of square error (SSE) is close to the 
minimum.  
 
Another iterative method is the simplex method, where the values for the initial estimate and the 
initial increment value for each parameter needs to be provided. This method starts with three 
starting values, and after several iterations the algorithm rejects the worst of the solutions 
generated. The advantages of this method over other non-linear regression algorithms include its 
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fast speed and its rare convergence to a local minimum. Hence, it can be used with non-
continuous functions. The disadvantages are that it does not estimate standard error for each 
parameter and is more difficult to use since the starting increments for each parameter need to be 
provided.
52,53
 
 
The Marquardt method has several advantages, the most important being that it combines the 
strengths of the methods, steepest descent and Gauss-Newton. Due to these advantages it has 
been used to optimize the rate constants in case of the presented studies with gabapentin.
52
 
 
Non-linear regression cannot find the best curve through a set of data points but can optimize the 
parameters in a specified equation that calculates ‘y’ as a function of ‘x’ and one or more 
parameters. The function is selected to describe a hypothetical physical or molecular model. All 
non-linear regression procedures calculate the derivative of ‘y’ with respect to all parameters. 
Some programs require the derivatives to be determined and entered as an equation, while other 
programs such as Excel Solver
®
 (used in this research), and calculate the derivatives numerically 
by evaluating the equations before and after altering the value of the parameter by a small 
amount. Initial estimates for each parameter in the equation need to be specified based on 
previous experience, preliminary analysis based on linear transformation, or on a hunch. It is not 
difficult to estimate parameters if one understands both the physical model that the equation 
represents and the meaning of each parameter. Poor selection of initial values results in longer 
processing times and may lead to the program going in a wrong direction and not converging to a 
solution. It is also possible that poorly selected values can cause the program to converge on a 
wrong solution.
52
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Another important parameter in non-linear regression is the convergence criterion, especially 
when calculations occur iteratively and the computer needs to be told when to stop. Too loose a 
criterion can cause the program to stop before it has reached the best fit. On the other hand too 
tight a criterion can result in consumption of the computer time. Considering the time limitation, 
a tight convergence criterion (10
-10
) was attempted across all the parameter estimates for 
gabapentin’s degradation in order to avoid convergence to a wrong solution.52,54 
 
When assessing goodness of fit, it is important to examine the graph of the curve superimposed 
to the data points. In addition to viewing the graph, two statistical methods can be used to 
quantitate goodness of fit:  
1. Root mean square (RMS) this takes into account the average deviation of the curve from the 
points. When considering the residuals plot (residual vs. ‘x’ value), the ‘y’ value of each point is 
replaced by the distance of that point from the curve. The residual value should be randomly 
distributed across the plot. If the equation is inappropriate, the residuals tend to cluster. This 
indicates systematic deviations of the data points from the predictions of the curve.  
2. The value of the square of correlation coefficient (R
2
) is important for non-linear regression 
when represented as a fraction of the variance in the ‘y’ value, reduced by the curve.52,54 
 
In non-linear regression, it is possible that the final fit is not the best possible fit. To guard 
against this issue one can repeat non-linear regression several times using different starting 
values, this provides a more intuitive grasp of the equations used.  
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In research studies with gabapentin the initial starting values were altered randomly as well as 
systematically using a central composite experiment design in a 4 (parameters) x 3 (levels) 
matrix. The range for altering the starting values was selected to be two orders of magnitude 
higher and lower than the parameter estimates published in previous studies with gabapentin.
1
  
 
1.3.6. Compaction as a Processing Condition 
One of the research studies presented in this document involved understanding the impact of 
compression pressure and powder properties of excipients on solid-state degradation of 
gabapentin. This study was designed to test the hypothesis that exposure of gabapentin to 
compaction pressure will increase lattice defects in gabapentin crystal and reduce its particle 
size resulting in an increase in the initial rate for lactam formation. To understand the impact of 
compaction pressure and powder properties of excipients, it is important to understand the 
theory behind tablet formation.
55
 
 
A tablet is formed by reducing the volume of particles consolidated into a single body. This 
process can be divided as a series of different phases. At the beginning, the volume starts to 
reduce and the particles are arranged into a closer packing structure. At a certain point, the 
packing properties and friction between particles will prevent any further particle 
rearrangement. At this point, further reduction in volume will result in an elastic, viscoelastic or 
plastic deformation of the particles. Additionally, fragmentation will result in generation of 
smaller particles, which will also undergo deformation resulting in volume reduction. Amongst 
the excipients used in the presented research, microcrystalline cellulose, HPC and HPMC 
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undergo plastic deformation, while talc, Emcompress
®
 and the drug gabapentin deform by 
brittle fragmentation.
56-67
  
 
The process of compaction will result in the particle surfaces being brought in close proximity 
with each other, leading to formation of inter-particulate bonds. Predominant bonding 
mechanisms include, mechanical interlocking between irregularly shaped particles, inter-
particulate attraction forces and creation of solid bridges due to melting of particles. The process 
of compaction will therefore result in increased particle contact and reduced particle size, both 
of which will affect the solid-state degradation of drugs.
61,63-65,68
  
 
A number of factors affect deformation mechanism. One such factor is material crystallinity. 
Amorphous materials undergo plastic deformation while most crystalline materials undergo 
brittle fragmentation.
69,70 
Particle size and shape are amongst other important determinants of 
deformation behavior. It has been observed that increasing the irregularity and roughness of 
granules changes the compression behavior from plastic deformation towards that of particle 
fragmentation and attrition.
71,72
 
 
Addition of glidants such as talc to the formulation results in decreased surface roughness of the 
drug particles by formation of a uniform coating of the glidant particle around the drug particle. 
This reduces the frictional drag between particles. Glidants also act as physical barriers between 
particles reducing the attractive forces between them and removing any surface adsorbed 
moisture to improve their flow properties.
73,74
 
 
 
 
33 
 
Moisture absorbed by amorphous regions in the  materials have a significant effect on physical 
and mechanical properties of formulations such as  flow, compression, hardness, surface energy, 
die-wall friction and Young’s elastic modulus.75 Moisture is responsible for plasticization of the 
material during the compression phase, thus affecting the bond formation processes.
76,75,77
 This 
highlights the need to understand the relationship between moisture content of the excipients 
and the rate of lactam formation in the compacts of gabapentin with excipients. 
 
Analysis of Powder Compaction Data 
Studying compaction mechanism for powders has become an important part in the development 
of solid oral dosage forms. Measurements related to the compaction of powders are facilitated 
by the availability of instrumented tablet presses, commonly known as compaction simulators. 
These instruments help measure punch force, upper and lower punch displacement, axial and 
radial load transmission and temperature changes. 
 
The Heckel Equation is amongst the most popular methods used in pharmaceutical research to 
determine the volume reduction mechanism during compression.
59,71,78,79
 It is based on the 
assumption that powder compression follows first order kinetics, with the inter-particulate voids 
as the reactant and the powder densification as the product. According to the Heckel 
relationship, the degree of compact densification with increasing compaction pressure is directly 
proportional to porosity (Equation 18). 
 
𝒅𝝆𝒓
𝒅𝑷
= 𝒌𝜺 Equation 18 
In the above equation, 𝜌𝑟 is the relative density at pressure P and 𝜀 is the porosity. 
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The relative density is defined as a ratio of density of the compact at pressure P, to the density 
of the compact at zero porosity (true density).  
 
Equation 19 is used in the calculation of porosity for gabapentin-excipient compacts to 
understand the effect of compact porosity on the initial rate for lactam formation. 
𝜺 = (
𝑽𝒑 − 𝑽𝟎
𝑽𝑷
) = 𝟏 − 𝝆𝒓 Equation 19 
 
In the above equation, 𝑉𝑝 and  𝑉0 are the volume at any applied pressure and volume at 
theoretical zero porosity respectively. Equation 18 and equation 19 can be used to derive 
equation 20. 
𝒅𝝆𝒓
𝒅𝑷
= 𝒌(𝟏 − 𝝆𝒓) Equation 20 
The differential equation in equation 20 can be solved to generate equation 21. 
𝒍𝒏 [
𝟏
(𝟏 − 𝝆𝒓)
] = 𝒌𝑷 + 𝑨 Equation 21 
  
The plot of equation 21 yields a graph with a linear portion having slope k and intercept A. 
The reciprocal of k gives a material dependent constant known as yield pressure (𝑃𝑦), which is 
inversely related to the ability of the material to deform plastically under pressure.
79-81
 The 
intercept of the extrapolated linear region A is a function of the original compact volume.  
 
The main utility of Heckel plots arises from their ability to identify predominant deformation 
behavior of a material. The Heckel relationship is explored in the presented research to 
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understand the predominant deformation mechanism of the excipients in the physical mixture 
with gabapentin, and for establishing any connection of this material property with accelerated 
lactam formation. 
 
1.3.7. Conclusion 
Gabapentin is used in the treatment of many neurological disorders with a major application 
being in the treatment of epilepsy. Gabapentin has a potential to undergo intramolecular 
cyclization to form its degradation product lactam. Lactam is 20-fold more toxic than 
gabapentin and has been reported to cause seizures in animal models. The concentration of 
lactam has been regulated to 0.4% by USP. A number of recalls worth millions of dollars have 
been issued in the last couple of years (2010-2013) due to the exceedingly high lactam content 
in gabapentin formulations. 
 
Literature findings have indicated an effect of pH, salt concentration and excipients on the 
solution state stability of gabapentin. In solid state gabapentin is known to undergo accelerated 
degradation under accelerated temperature conditions and application of processing conditions 
such as milling and lyophillization. One study has highlighted potential effect of excipient type 
on its degradation kinetics. 
 
The main objective of this project was to test for the effect of excipient properties on 
gabapentin’s degradation profile. In order to test the role of excipients a robust and accurate 
analytical method was developed and validated for the quantification of gabapentin and lactam. 
The overlying objective was to develop a relationship between the rate constant for lactam 
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formation and properties of excipients affecting the degradation kinetics. The final objective 
was to identify the effect of compaction as a processing condition on gabapentin’s degradation 
profile considering its commercial availability as a solid oral dosage form. 
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Chapter 2 
Optimization and Validation of the Analytical Method for Determination of 
Gabapentin and Its Degradation Product Lactam 
 
2.1. Introduction 
The objective of this dissertation is to identify various factors related to formulation composition 
and compaction, which affect the solid-state stability of gabapentin. An important step toward 
fulfilment of this objective is the accurate quantification of gabapentin and lactam in their binary 
mixtures and in their compacts with excipients. Thus, selecting an analytical method, optimizing 
and validating the same as per established guidelines, are a key aspects of the project.  
 
Literature studies indicate a number of analytical methods using different instrumental 
techniques for the separation and quantification of gabapentin and lactam. When selecting a 
method, it is important to note that gabapentin is a highly polar compound which is poorly 
retained on most reverse-phase high performance liquid chromatography (RP-HPLC) columns. 
On the other hand, its degradation product, lactam, is strongly retained on RP-HPLC columns. 
Due to gabapentin’s poor column retention, most analytical methods involve extraction and 
derivatization steps before quantitative determination.
36
 The quantification of gabapentin in 
human plasma and serum has been reported using gas chromatography, capillary electrophoresis 
and HPLC techniques.
52, 82-86
 Analytical techniques developed for bioanalysis of gabapentin also 
include mass spectrometry in combination with gas or liquid chromatography.
52,85,86
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An analytical method using HPLC instrumentation along with UV detection and without 
derivatization has been developed for the successful determination of potency for gabapentin in 
its marketed formulations.
5,36
 The separation is achieved using a cyano column with an isocratic 
elution method. The cyano column is selected due to the higher retention time of gabapentin 
relative to the retention time on other C18 columns for organic molecules. The other reason stated 
for column selection has been to exploit the combination of hydrophilic and hydrophobic 
interactions of the cyano groups with compounds possessing amine or amide functional groups, 
which are found in both gabapentin and lactam. The method used a higher volume (95% v/v) of 
the aqueous phase relative to the organic phase to increase the retention time (71 min) for lactam. 
The buffered aqueous phase had a neutral pH (6-7), since low pH conditions resulted in poor 
resolution between gabapentin and lactam in addition to poor stability of gabapentin.
5,36
  
 
The above method offered several advantages. Thus, it was selected, optimized (to improve its 
specificity), and validated as per ICHQ2A guidelines. Along with the method validation, 
preliminary studies to test the interference of excipients and filter membrane on the extraction 
efficiency of gabapentin and lactam were performed. The stability of gabapentin and lactam in 
the mobile phase and in the sample solvent was studied to negate the effect of solution state 
kinetics confounding the observed degradation of gabapentin in its solid-state. 
 
2.2. Materials and Methods 
2.2.1. Materials 
Gabapentin was obtained from Hangzhou Starshine Pharmaceutical Co. Ltd. (Hangzhou, China). 
Gabapentin reference standard was purchased from the United States Pharmacopeia (USP) 
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(Rockville, Maryland). Lactam standards were purchased from USP for the validation studies 
and Sigma-Aldrich (St. Louis, Missouri) for all other preliminary studies. The excipients used in 
the study included calcium phosphate dibasic dihydrate (Emcompress
®
, E. Mendell. Co. Inc, 
New York), monobasic calcium phosphate (V-90 grade, Innophos, New Jersey), dibasic calcium 
phosphate anhydrous (A-Tab
®
, Innophos, New Jersey), tribasic calcium phosphate anhydrous 
(Tri-Tab
®
, Innophos, New Jersey), modified corn starch (Uni-pure
TM
 DW, National starch LLC, 
New Jersey), hydroxypropyl cellulose (HPC, Klucel EF
®
, Ashland Inc., Kentucky), 
hydroxypropyl methyl cellulose (HPMC, Methocel
TM
 E50 Prem LV, Dow Chemical Co., 
Michigan) and talcum (Talc, Fisher Scientific, Massachusetts).  HPLC grade monobasic 
potassium phosphate and dibasic potassium phosphate were purchased from Sigma-Aldrich (St. 
Louis, Missouri) for mobile phase preparation. HPLC grade acetonitrile was purchased from 
VWR International (Radnor, Pennsylvania). Deionized water filtered through a 0.45 micron filter 
was obtained from an in-house Milli-Q water purification system (Millipore Corporation, 
Billerica, Massachusetts). Nylon syringe filters (0.4 µm) for sample filtration and nylon filters 
(0.2 µm) for mobile phase filtration were purchased from VWR International (Radnor, 
Pennsylvania).  
 
2.2.2. Instrumentation and chromatographic condition  
The method used a reverse phase HPLC system (Waters
®
 2890 separation module) equipped 
with an ultra-violet (UV) photodiode array detector. The column selected was a μ-Bondapack 
cyano column (3.9 mm x 390 mm) (Waters Co. Op. Massachusetts).
87
  The mobile phase was 
composed of 95 parts phosphate buffer pH 6.8-7.0 (10 mM KH2PO4/ 10 mM K2HPO4) and  
5 parts of acetonitrile. The mobile phase pH was adjusted to 6.8 to ascertain maximal stability of 
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gabapentin in solution. The mobile phase pH was measured using pH meter H12210 (Hanna 
Instruments, Carrolton, Texas). The mobile phase was filtered using a nylon filter (0.2 µm) and 
degassed 1 h prior to analysis. Flow rate of the mobile phase was adjusted at 1.0 ml/min and the 
injection volume of 20 µl was selected. Detection of gabapentin and lactam was performed at a 
single wavelength of 210 nm with the column maintained under ambient temperature conditions 
(20-22°C). 
 
2.2.3. Analytical Method Validation 
The analytical method was validated for specificity, assay, linearity, range, accuracy, precision, 
limit of detection, and limit of quantification. The protocol for all designed studies and the data 
reporting was as per ICH Q2A guidelines. 
 
Specificity 
Specificity of the method was determined by analyzing all single components, namely 
gabapentin (2 mg/ml), lactam (40 μg/ml), and excipients (2 mg/ml) such as Emcompress®, A-
Tab
®
, Tri-Tab
®
, Mono-Tab, HPMC, HPC, starch and talc used in the stability studies. All 
chromatograms were evaluated to confirm the absence of similar elution times for gabapentin, 
lactam, or any other confounding peaks from the excipients to be used in the study subsequently. 
 
Assay (Determination of Purity) for Bulk Gabapentin 
Gabapentin stock solution I (5 mg/ml) was prepared using the USP reference standard for 
gabapentin in deionized filtered water as a medium for standard preparation. For complete 
solubilization of gabapentin, the standard solution was sonicated for a minute. The stock solution 
I was then used to prepare calibration standards (n = 3) at 5 different concentration levels by 
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using a serial dilution technique. The five concentrations ranged from 0.5 mg/ml to 5 mg/ml. The 
calibration was repeated on 3 separate days to determine the inter-day precision. The calibration 
standards were then used to determine the purity of the bulk gabapentin procured for the 
degradation studies.  
 
Another stock solution II (5 mg/ml) of gabapentin was prepared using bulk gabapentin, which 
was diluted with filtered deionized water to prepare sample solutions (n = 6) of low (0.5 mg/ml), 
medium (2 mg/ml) and high (5 mg/ml) concentrations. The purity of gabapentin was determined 
based on the linear equation of the calibration curve for gabapentin using calibration standards. 
The purity of bulk gabapentin is reported as average percent purity (n = 6) relative to the 
reference standard and precision has also been reported as percent relative standard deviation  
(% RSD) amongst the replicates and confidence interval (95%) (n = 6). 
 
Linearity and Range 
Standard calibration curves were prepared using six calibrators (3 concentrations x 2 inj.) for 
gabapentin over a range of 0.4–10 mg/ml and six calibrators (3 concentrations x 2 inj.) for lactam 
over a range of 8–240 µg/ml on three separate days. The data of peak area versus drug 
concentration was treated by linear least square regression analysis. The standard curves were 
evaluated for inter-day and intra-day linearity. 
 
Preparation of Standard Solutions for Calibration 
A gabapentin stock solution III (20 mg/ml) was prepared using bulk gabapentin. Calibration 
standards were prepared at 6 different concentration levels ranging between 0.4 mg/ml and  
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10 mg/ml. A concentration range was selected, keeping in mind the larger mass of gabapentin 
 (200 mg) to be used for the accelerated stability studies. A lactam stock solution I (5 mg/ml) 
was prepared using the USP reference standard. Since lactam is the degradation product 
measured, the ability to detect and quantitate smaller concentrations was important. Keeping this 
in mind, calibration standards were prepared for concentrations ranging between  
8 µg/ml-240 µg/ml.  
 
A gabapentin stock solution IV (20 mg/ml) was used to prepare quality control solutions at low 
(0.4 mg/ml), medium (4 mg/ml), and high (10 mg/ml) concentrations. Similarly, a lactam stock 
solution II (5 mg/ml) was used to prepare quality control solutions at low (8 µg/ml), medium  
(40 µg/ml) and high (240 µg/ml) concentrations. 
 
All of the above quality control and calibration standards were prepared using filtered deionized 
water as a diluting medium. The above solutions were prepared in triplicates, on three different 
days as part of the method validation. 
 
Accuracy and Precision 
The accuracy and precision of three different concentrations of gabapentin and lactam were 
determined in triplicates. The analysis was performed on quality control solutions across the 
calibration range on three separate days. The method accuracy was established by evaluating the 
amount of gabapentin and lactam in the quality control solutions using the calibration standards. 
The accuracy results are expressed as percent recovery (n = 3) of gabapentin and lactam from the 
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quality control solutions. Precision, both inter-day and intra-day, is expressed as  
%RSD (n = 3) for peak areas of gabapentin and lactam. 
 
Limit of Detection and Limit of Quantitation 
Limit of detection (LOD) and limit of quantitation (LOQ) for gabapentin and lactam were 
calculated based on standard deviation of response (𝜎) and slope (s) of the calibration curves. 
LOD is calculated as 3.3× (𝜎/𝑠) and LOQ is calculated as 10× (𝜎/𝑠). The response (𝜎) is the 
standard deviation of intercepts and (s) is the average value of slope from the linear regression 
equation of the calibration curves (n = 3). The calibration curves were developed in the 
concentration range of 0.4 mg/ml–10 mg/ml for gabapentin and 8 mg/ml and 240 mg/ml for 
lactam.   
 
2.2.4. Method Optimization 
Effect of Filter Membrane  
The possibility of drug-filter membrane (nylon) interaction was determined by studying the 
recovery of gabapentin and lactam from solutions of known concentrations and volume (2.5 ml). 
The protocol involved passing the solutions twice through the syringe filter of a known pore size  
(0.45 µm). 
 
Quality control solutions (n = 2) of gabapentin at low (0.5 mg/ml) and high (5 mg/ml) 
concentrations, and thoseof lactam at low (8 µg/ml) and high (240 µg/ml) concentrations were 
filtered twice using a nylon syringe filter (0.45 µm/ 25 mm). Both the filtrates (F1 and F2) were 
quantified for the concentration of gabapentin and lactam. The data is reported as the average  
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(n = 2) percent recovery of gabapentin and lactam and average precision (%RSD, n = 2) for the 
recovery of gabapentin and lactam from the filtrates. 
 
Effect of Excipients  
The analytical method was used to determine the extraction efficiency for gabapentin and lactam 
in the presence of excipients, namely, Emcompress
®
, HPMC, starch, talc, and HPC. These 
excipients were used in the stability studies with gabapentin. Physical mixtures (n = 2) of 
gabapentin and excipient in a 1:1 proportion were prepared manually. The extraction efficiency 
of lactam was determined by spiking its known concentration (200 µg) in the physical mixture. 
The solutions prepared in deionized filtered water were sonicated for 10 min, filtered using a 
nylon syringe filter (0.45 µm) and analyzed for the concentrations of gabapentin and lactam. 
 
2.2.5. Stability of gabapentin and lactam 
The stability of the aqueous solutions of gabapentin and lactam in the medium (deionized filtered 
water) for sample preparation and in the mobile phase was determined. Samples of gabapentin  
(10 mg/ml) and lactam (160 µg/ml) were prepared in deionized filtered water and stored under 
room temperature conditions (20-22°C) in the dark for 24 h. The samples were analyzed for the 
recovery of lactam and gabapentin, as well as for identification of any new products generated. 
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2.3. Results and Discussion 
2.3.1. Analytical Method Validation 
 
Specificity 
The sample chromatogram for gabapentin (2 mg/ml) is shown in Figure 6 and that for lactam  
(40 µg/ml) is shown in Figure 7. Retention time (n = 18) for gabapentin was 3.75 min 
(±0.009 min) and that for lactam is 7.61 min (±0.056 min). The peaks of both gabapentin and 
lactam were well separated from each other and could be analyzed accurately. The study to test 
the matrix effect confirmed absence of any co-eluting peaks, related to the excipients, at the 
retention times of lactam and gabapentin (appendix 1).  
 
Figure 6: Sample chromatogram for gabapentin (2 mg/ml). The retention time is 3.75 min 
(±𝟎. 𝟎𝟎𝟗 𝐦𝐢𝐧, 𝐧 = 𝟏𝟖). The solvent front is seen eluting at 2.5 min. 
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Figure 7: Sample chromatogram for lactam (40 µg/ml). The retention time is 7.61 min 
(±𝟎. 𝟎𝟓𝟔 𝐦𝐢𝐧, 𝐧 = 𝟏𝟖). 
 
Assay for Purity Determination of Bulk Gabapentin 
Bulk gabapentin was evaluated for its purity relative to its reference standard (USP). This step 
was initiated to approve the use of bulk gabapentin in subsequent stability studies and analytical 
method validation. Results for the calibration curve using the gabapentin reference standard are 
reported in Table 2 and depicted in Figure 8. The results showed good correlation (R
2≥0.999) 
between peak area and gabapentin concentration. The results for percent recovery and precision 
among replicates are reported in Table 3. The results suggested bulk gabapentin to possess purity 
comparable to that of the reference standard. The percent purity and precision  
(% RSD) of bulk gabapentin was 97.64% and 2.42% at low concentration (0.5 mg/ml), 102.44% 
and 0.75% at medium concentration (2 mg/ml), and 100.49% and 0.28% at high concentration  
(5 mg/ml) respectively. Hence, for subsequent studies involving gabapentin, the use of bulk 
gabapentin was considered appropriate.  
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Table 2: Calibration curve data using the gabapentin reference standard (USP). The 
calibration was performed as per ICH Q2A guidelines on three separate days. 
Linearity and Range for Calibration Curves Using Gabapentin Reference Standard (USP)  
Standard Curve 
Analytical Range 
(mg/ml) 
Calibrators Slope y-intercept 
R
2
 
Value 
validation Day 1  0.5-5 5 509910 20062 0.9995 
validation Day 2 0.5-5 5 504610 21739 0.9998 
validation Day 3 0.5-5 5 504710 26862 0.9994 
 
 
 
Figure 8: Calibration curves for gabapentin reference standard (USP) solutions. 
Calibration was performed as per ICH Q2A guidelines on three separate days. The 
equations represent linear correlation of the peak area for gabapentin and its 
concentration on the three days of calibration. 
 
 
 
 
 
y = 5.0461E+05x + 2.1739E+04 
R² = 9.9984E-01 
y = 5.0991E+05x + 2.0062E+04 
R² = 9.9951E-01 
y = 5.0472E+05x + 2.6862E+04 
R² = 9.9946E-01 
0
500000
1000000
1500000
2000000
2500000
3000000
0 1 2 3 4 5 6
P
e
ak
 A
re
a 
Concentration (mg/ml) 
 
 
48 
 
Table 3: Purity of bulk gabapentin for the analysis performed at three different 
concentrations. 
Gabapentin Purity: Bulk Drug Substance n = 6 (3 Rep. x 2 inj.)) 
  Solution Concentration 
  0.5 mg/ml 2 mg/ml 5 mg/ml 
% Purity 97.64 102.44 100.49 
%RSD (Precision) 2.42 0.75 0.28 
Confidence Interval 
(95%) 
2.48 0.81 0.29 
 
 
Linearity and Range 
The linearity for standard calibration curves was established in the analytical range 0.4-10 mg/ml 
for gabapentin and 8-240 µg/ml for lactam. The results for linearity are summarized in Table 4 
for gabapentin and in Table 5 for lactam. The results indicate good correlation (R
2≥0.999) 
between peak area and concentration for gabapentin and lactam in the analytical range selected, 
as seen in Figure 9 and Figure 10. 
Table 4: Linearity of calibration curves for gabapentin. Calibration was performed as per 
ICH Q2A guidelines on three separate days. Slope, intercept, and the correlation coefficient 
for the peak area and concentration plot have been reported. 
Linearity of Calibration Curves for Gabapentin 
Standard Curve 
Analytical Range 
(mg/ml) 
Calibrators Slope y-intercept R
2
 Value 
Validation Day 1  0.4-10 6 549805 790.12 0.9995 
Validation Day 2 0.4-10 6 539610 - 15428 0.9994 
Validation Day 3 0.4-10 6 549788 18649 0.9999 
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Figure 9: Calibration curves for gabapentin (Method Validation). Calibration was 
performed as per ICH Q2A guidelines on three separate days. The equations represent the 
linear correlation between the peak area for gabapentin and its concentration on the three 
days of calibration. 
 
Table 5: Linearity of calibration curves for lactam. Calibration was performed as per ICH 
Q2A guidelines on three separate days. Slope, intercept and the correlation coefficient for 
the peak area and concentration plot have been reported. 
Linearity Data of Calibration Curves for Lactam 
Standard Curve Analytical Range (mg/ml) Calibrators Slope y-intercept R
2
 Value 
Validation Day 1  8-240 6 10382 -326.55 0.9999 
Validation Day 2 8-240 6 10392 579.55 0.9999 
Validation Day 3 8-240 6 10577 1016.3 0.9999 
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Figure 10: Calibration curves for lactam (Method Validation). Calibration was performed 
as per ICH Q2A guidelines on three separate days. The equations represent linear 
correlation between the peak area for gabapentin and its concentration on the three days of 
calibration. 
 
Accuracy and Precision 
The results for the accuracy and precision of analytical quality control samples are summarized 
in Table 6 and Table 7 for gabapentin and in Table 8 and Table 9 for lactam. Method accuracy 
was recorded to be greater than 97% at all concentration levels on all three days for gabapentin. 
Method accuracy was also seen to be greater than 98% at all concentration levels on all three 
days for lactam. Method precision (n = 3), represented as %RSD was seen to be lower than 2.5% 
for both gabapentin and lactam. Inter-day and intra-day precisions were recorded to be lower 
than 2% RSD as well. 
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Table 6:Determination of accuracy for the analytical method using gabapentin. The 
method accuracy was determined at three separate concentration levels on three separate 
days. 
Gabapentin Accuracy: Drug Substance (% Recovery n = 3) 
  Solution Concentration 
  0.4 mg/ml 4 mg/ml 10 mg/ml 
Validation Set 1 98.48 97.46 98.11 
Validation Set 2 100.27 97.79 100.09 
Validation Set 3 99.41 100.29 101.82 
 
Table 7:Determination of precision for the analytical method using gabapentin. Method 
precision was determined at three separate concentration levels on three separate days. 
Gabapentin Precision: Drug Substance (%RSD n = 3) 
  Solution Concentration 
  0.4 mg/ml 4 mg/ml 10 mg/ml 
Validation Set 1 0.39 1.29 1.68 
Validation Set 2 0.26 0.07 1.64 
Validation Set 3 2.2 0.15 0.51 
Inter-day 0.9 1.57 1.85 
 
Table 8:Determination of accuracy for the analytical method using lactam. Method 
accuracy was determined at three separate concentration levels on three separate days. 
 
Lactam Accuracy: Drug Substance (% Recovery n = 3) 
  Solution Concentration 
  8 µg/ml 40 µg/ml 160 µg/ml 
Validation Set 1 99.02 99.31 99.95 
Validation Set 2 99.05 100.05 99.74 
Validation Set 3 101.63 99.36 98.23 
 
Table 9:Determination of precision for the analytical method using lactam. Method 
precision was determined at three separate concentration levels on three separate days. 
Lactam Precision: Drug Substance (%RSD n = 3) 
  Solution Concentration 
  8 µg/ml 40 µg/ml 160 µg/ml 
Validation Set 1 0.57 0.44 0.3 
Validation Set 2 0.56 0.25 0.12 
Validation Set 3 2.22 0.22 0.98 
Inter-day 1.49 0.41 0.94 
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Limit of Detection and Limit of Quantitation 
The limit of detection and the limit of quantitation for gabapentin were 57 µg and 174 µg, 
respectively, while the limit of detection and the limit of quantitation for lactam were 0.15 µg 
and 0.47 µg, respectively. Greater sensitivity for the detection of lactam relative to gabapentin is 
due to its higher ultraviolet absorptivity, which is known to be almost one order magnitude 
greater than that for gabapentin. 
 
2.3.2. Method Optimization 
Effect of Filter Membrane  
The propensity of gabapentin and lactam to adsorb on the surface of the filter membrane used in 
the stability studies was tested. The results of the study are reported in Table 10. The results 
suggested complete recovery (100% ±3% w/w) of both gabapentin and lactam at high as well as 
low concentrations, for both the filtrates. The recovery for gabapentin at low concentration  
(0.5 mg/ml) was 99.46% for the first filtrate and 97.93% for the second filtrate.  At a higher 
concentration (5 mg/ml) the recovery of gabapentin was 100.15% and 100.46% for the two 
filtrates tested. In the case of lactam, the recovery at a low concentration (8 µg/ml) was 103.6% 
and 103.3% for the two filtrates, and at a higher concentration (240 µg/ml) the recovery was 
99.4% and 100.1% for the two filtrates. Precision (%RSD, n = 3) for the recovery of gabapentin 
and lactam post-filtration was seen to be below 2%. 
 
 
 
 
 
53 
 
Table 10: The effect of the filter membrane on the recovery of gabapentin and lactam. The 
recovery was analyzed for solutions of gabapentin and lactam at two different 
concentrations, passed through the filter twice.  
Recovery of Compounds Post Filtration Using Syringe Filter (Nylon, 0.45 µm) 
Compound Concentration / Filtrate %Recovery (n = 3) %RSD (n = 3) 
Gabapentin Low 0.5 mg/ml / F1 99.46 0.92 
  Low 0.5 mg/ml / F2 97.93 1.14 
  High 5 mg/ml / F1 100.15 0.22 
  High 5 mg/ml / F2 100.46 0.21 
Compound Concentration / Filtrate %Recovery (n = 2) %RSD (n = 2) 
Lactam Low 8 µg/ml / F1 103.3 0.23 
  Low 8 µg/ml / F2 103.66 1.7 
  High 240 µg/ml / F1 99.4 0.26 
  High 240 µg/ml / F2 100.18 0.06 
* F1 = First Filtrate, F2 = second Filtrate 
Effect of Excipients  
The results for the recovery of gabapentin and lactam in the presence of excipients are reported 
in Table 11. The recovery was seen to be greater than 97% for both gabapentin and lactam in the 
presence of most excipients. The precision (%RSD, n = 2) for the recovery was seen to be less 
than 3%. 
 
Table 11: Results for the recovery of gabapentin and lactam in the presence of excipients. 
Physical mixtures of gabapentin and lactam with the excipients were analyzed to determine 
the effect of excipients on the extraction of either gabapentin or lactam in solution. 
Recovery of Compounds in the Presence of Excipients  
Compound Excipients %Recovery  (n = 2) %RSD (n = 2) 
Gabapentin Emcompress® 98.62 0.57 
  talc 97.99 0.6 
  HPMC 97.73 0.09 
  starch 97.54 2.23 
Lactam Emcompress® 99.22 0.88 
  talc 98.56 0.11 
  HPMC 105.24 1.02 
  starch 97.67 2.47 
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2.3.3.   Stability of Gabapentin and Lactam  
Lactam was found to be stable in an aqueous medium and under ambient temperature (22°C) and 
humidity (30% RH) conditions for 24 h. Complete recovery (100% w/w) was observed for 
lactam, while greater than 99% w/w recovery was observed for gabapentin. A small peak for 
lactam (2 µg/ml) was seen eluting post 24 h from the gabapentin solution (10 mg/ml) (Figure 
11). The degradation rate of gabapentin to lactam in solution was analyzed to be as low as 
0.0008% mole/h. The total time gabapentin would be maintained in its solution state before 
analysis was controlled to be less than 2 h. The preparation of samples prior to analysis 
confirmed minimal (<0.0016% mole) lactam formation in the gabapentin solution at the time of 
analysis.  
 
  
Figure 11: Chromatogram depicting the stability of gabapentin in the solution. A small 
peak of lactam is seen eluting from the gabapentin sample stored for 24 h in dark under 
ambient temperature and humidity conditions. The degradation rate for gabapentin in 
solution was calculated to be <0.0008% mol/h. 
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2.4. Conclusion 
The gabapentin (bulk) procured for the dissertation work was determined to be of purity 
comparable to its reference standard. The HPLC method was successfully validated for accuracy, 
precision, linearity, specificity, LOD and LOQ for gabapentin and lactam as per ICH Q2A 
guidelines.  
 
The method demonstrated specificity for gabapentin and lactam in the presence of excipients, 
mobile phase medium, and water. The filters and the excipients in the study did not affect the 
recovery of either gabapentin or lactam. Lactam was found to be stable in the solution medium 
and mobile phase throughout the study duration. On the other hand, gabapentin was found to 
convert at a very low rate in the solution under controlled pH conditions.  
 
The method was therefore, considered suitable for the assessment of the solid-state stability of 
gabapentin and for quantifying its degradation product, lactam, in the presence of excipients.  
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Chapter 3 
Investigating the Effect of Excipients on the Solid-State Degradation of 
Gabapentin 
 
3.1.   Introduction 
As discussed in chapter 1, the degradation of drug molecules is accelerated by the presence of 
excipients. This effect is either due to the chemical interactions between excipients and drug 
molecules or due to the physical properties of the excipients.
2
  
 
Commercially available solid dosage forms of gabapentin include film-coated tablets and hard-
shelled capsules. Formulating a strong and non-friable solid dosage form of gabapentin requires 
the addition of excipients to improve its poor compressibility and poor flow properties. Typical 
excipients used in gabapentin formulations include tablet diluents such as dibasic calcium 
phosphate, binders such as HPC and corn starch, film coating polymers such as HPMC, flow 
enhancers such as talc and lubricants such as magnesium stearate. 
 
An important aspect of this research is to provide evidence for the accelerating effect of 
excipients on the solid-state degradation of unprocessed gabapentin. The identification of 
excipient properties that contribute to this effect will be explored in the next chapter. 
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3.2. Materials and Methods 
3.2.1.  Materials 
The model drug gabapentin (Hangzhou Starshine Pharmaceutical Co. Ltd., Hangzhou, China, 
Batch 0803023) was procured for the stability studies. The excipients to be used in the stability 
studies were selected based on commercially used excipients in gabapentin formulations and 
other commonly used tableting excipients. The excipients selected include calcium phosphate 
dibasic dihydrate (Emcompress
®
, E. Mendell. Co. Inc, New York), monobasic calcium 
phosphate anhydrous (Mono-Tab, V-90 grade, Innophos, New Jersey), dibasic calcium 
phosphate anhydrous (A-Tab
®
, Innophos, New Jersey), tribasic calcium phosphate anhydrous 
(Tri-Tab
®
, Innophos, New Jersey), modified corn starch (Uni-pure
TM
 DW, National Starch LLC, 
New Jersey), hydroxypropyl cellulose (HPC, Klucel EF
®
, Ashland Aqualon Functional 
Ingredients., Delaware), hydroxypropyl methyl cellulose (HPMC, Methocel
TM
 E50 Prem LV, 
The Dow Chemical Co., Michigan) and talcum (Talc, Fisher Scientific, Massachusetts). All other 
reagents and solvents procured for analytical quantitation were of HPLC grade.  
 
3.2.2    Material Pretreatment 
Specific sieve fractions of the drug and the excipients were obtained by sieve classification using 
a set of standard sieves (Gilson Company, Inc.) and a sieve shaker (Performer III Model SS-3, 
Gilson Company, Inc.). The fractions retained on the sieves were weighed at intervals ranging 
from 20-25 min, until the measured weight change between sieving was less than 0.5% w/w.  
Specific particle size fraction between 125-250 µm was used for gabapentin and excipients (such 
as Emcompress
®
, Modified corn starch, HPC and HPMC).  However, a different particle size 
fraction (75-125 µm) of the phosphate salts, (such as Tri-Tab
®
, A-Tab
®
 and monobasic calcium 
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phosphate (Mono-Tab) was used, due to the limited quantity of the larger particle size fraction 
( ≥125 µm) for Mono-Tab on sieving. Talc was used as supplied in all experimentation, due to 
its smaller particle size (100% <75 µm), which precluded classification by sieving. 
 
Gabapentin, due to its reportedly poor stability under low humidity conditions, was equilibrated 
under controlled conditions of temperature (20°C ±2°C) and humidity (33% RH, magnesium 
chloride) for one week prior to the study.
5
 However, to prevent any confounding effects of 
moisture from the excipients, they were equilibrated under controlled conditions of high 
temperature (50°C) and  low humidity (5% RH, Drierite
®
) for at least one week prior to the 
study. 
  
 3.2.3.  Determination of Moisture Content 
The moisture content (% w/w) of the excipients was determined using thermogravimetric 
analysis (TGA Q-500, TA Instruments, Delaware). The materials (25-50 mg) were heated from 
ambient temperatures (25-30°C) to 110°C and maintained isothermally until the observed change 
in the sample weight was less than 0.2% w/w per minute. Average value and standard deviation 
of two replicate measurements is reported. 
 
 3.2.4.   Physical Mixture Preparation and Study Conditions 
To understand the effect of excipients on gabapentin’s stability profile, binary mixtures (n = 3) of 
gabapentin and excipients, namely, Emcompress
®
, A-Tab
®
, Tri-Tab
®
, HPMC, HPC, starch, 
Mono-Tab, and talc were prepared in a 1:1 proportion by weight. Binary mixtures were prepared 
manually using the geometric dilution technique with the help of a spatula. 
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All of the physical mixtures were observed under an optical microscope (Model BX-51, 
Olympus, Pennsylvania) to determine the role of excipient morphology, and size of the excipient 
particle on their distribution around gabapentin particles. Samples (n = 4) from different areas of 
the physical mixture were collected and observed under low magnification (4x). Morphology of 
the individual components was observed under higher (10x) magnification using the microscope.   
 
To understand the effect of the mixing procedure on gabapentin’s degradation, gabapentin 
samples (n = 3), controlled for their particle size (125-250 µm) were analyzed for lactam 
formation, with and without application of the mixing procedure (manual mixing in a geometric 
proportion using a stainless steel spatula).     
 
Previous research has indicated the stabilizing effect of environmental moisture on gabapentin’s 
degradation profile. The possibility of a similar stabilizing effect due to excipient moisture 
content cannot be refuted. Even though the excipients used in the study had low moisture content 
(<3% w/w), ascertaining a negligible impact of the excipient moisture content on the degradation 
of gabapentin was important.  The study to determine the effect of excipient moisture was 
performed using Mono-Tab, which inherently possessed low moisture content (0.01% w/w). 
Mono-Tab was mixed with water to account for a total of 1% moisture. Physical mixtures of 
gabapentin and Mono-Tab with variable moisture content (0.01% w/w and 1% w/w) were 
prepared, stored under accelerated conditions of temperature and humidity (50°C, 5% RH) and 
analyzed using the HPLC technique. The effect of excipient moisture on the kinetics degradation 
kinetics of gabapentin was further studied using HPMC equilibrated under different relative 
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humidity conditions (33% RH, 85% RH). The moisture content of the HPMC samples prior to 
physical mixing was recorded using thermo-gravimetric analysis (TGA).  
 
All of the degradation studies were performed in scintillation vials (20 ml) under accelerated 
conditions of temperature (50°C) and humidity (5% RH) for the entire duration (697 h) of the 
study. Samples (n = 3) were withdrawn periodically for quantitation of gabapentin and its 
degradation product lactam. Deionized and filtered (0.45 µm) water was used to prepare the 
sample solutions. The sample solutions were filtered using a 0.45 µm nylon syringe filter prior to 
the HPLC analysis. Data is reported as mean lactam concentration (% mole) over time (h) and 
error bars represent the confidence interval (95%) for three replicates at every time point. 
 
The existing kinetic model
1
 (Figure 4, pg. 13 ) for solid-state degradation of gabapentin was used 
to understand the effect of excipients on gabapentin’s degradation profile.1  The Runge - Kutta 
4
th
 order numerical approximation method was used to solve the series of differential equations 
defining the kinetic model using Excel
®
 (2010, Microsoft
®
, Redmond, Washington).
1
 Matlab
®
 
(R-2013, MathWorks
®
, Natick, Massachusetts), with its ode45 function handle (based on the 
Runge-Kutta algorithm), was used to validate the results of the numerical approximations 
calculated on Microsoft Excel
®
. 
  
The parameters of the differential equations (Equation 1-3, pg. 13), especially rate constants k1 
(autocatalytic branching), k2 (spontaneous dehydration), k3 (branching termination), and gaba0
*
 
(initial concentration of reactive gabapentin molecules) were optimized using the least square 
approach by the Solver function (Excel Solver
®
, Microsoft Office
®
 2010). A generalized reduced 
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gradient (GRG) method based on the Levenberg-Marquardt algorithm with a forward derivative 
was selected, a convergence criterion was set at 10
-10
, and a maximum of 1000 iterations were 
allowed when parameterizing the model. Constraints were established in order to obtain 
physically meaningful parameter estimates. One major constraint applied did not allow the 
values of k1 and k3 to be lower than 10
-8
 in order to prevent the estimation of zero valued 
parameters.  
 
A common issue encountered when optimizing parameters using non-linear regression is 
ensuring that the solution obtained is not a local minimum. To confirm that a global solution was 
reached, a central composite design of experiments (CCD) (Table 12) was used to generate a 
systematic combination of initial values over a broad range. The range for input values was 
established based on the reported literature parameter estimates (k1 = 7.10x10
-5
, k2 = 0.020, and 
k3 = 3.60x10
-5
) under similar experimental conditions (50°C, 5% RH). 
1
 A total of 25 different 
combinations of input values were used during the optimization process. Input values for the 
parameters k1 and k3 were varied in the range 0.000001-0.0001 mol
-1
h
-1
, while the value of k2 
was varied between 0.1-0.00001 h
-1
, and the value of gaba0
*
 were varied between 0.1-5% mole 
respectively. 
 
 
 
 
 
 
 
62 
 
Table 12: Application of a central composite design (CCD) approach to generate different 
systematic combinations of input parameter values. Range for the parameter values is 
selected based on previously published estimates. 
 
CCD Input Values for Parameter Optimization k1,k3 Range 
k1 (mol
-1
h
-1
) k2 (h
-1
) k3 (mol
-1h-1
) 
gaba0
*
(% 
mole) High 1x10
-4
 
1x10
-6
 1x10
-6
 1x10
-6
 0.1 Low 1x10
-6
 
1x10
-6
 1x10
-6
 1x10
-6
 5 Medium 5x10
-5
 
1x10
-6
 1x10
-6
 1x10
-4
 0.1     
1x10
-6
 1x10
-6
 1x10
-4
 5 k2 Range 
1x10
-6
 0.1 1x10
-6
 0.1 High 0.1 
1x10
-6
 0.1 1x10
-6
 5 Low 1x10
-6
 
1x10
-6
 0.1 1x10
-4
 0.1 Medium 0.05 
1x10
-6
 0.1 1x10
-4
 5     
1x10
-4
 1x10
-6
 1x10
-6
 0.1 gaba0
*
 Range 
1x10
-4
 1x10
-6
 1x10
-6
 5 High 5 
1x10
-4
 1x10
-6
 1x10
-4
 0.1 Low 0.1 
1x10
-4
 1x10
-6
 1x10
-4
 5 Medium 2.55 
1x10
-4
 0.1 1x10
-6
 0.1 
  1x10
-4
 0.1 1x10
-6
 5 
  1x10
-4
 0.1 1x10
-4
 0.1 
  1x10
-4
 0.1 1x10
-4
 5 
  1x10
-6
 0.05 5x10
-5
 2.55 
  1x10
-4
 0.05 5x10
-5
 2.55 
  5x10
-5
 1x10
-6
 5x10
-5
 2.55 
  5x10
-5
 0.1 5x10
-5
 2.55 
  5x10
-5
 0.05 1x10
-6
 2.55 
  5x10
-5
 0.05 1x10
-4
 2.55 
  5x10
-5
 0.05 5x10
-5
 0.1 
  5x10
-5
 0.05 5x10
-5
 5 
  5x10
-5
 0.05 5x10
-5
 2.55 
   
Uncertainty (standard error) for the estimated parameters was calculated using a macro 
(Solveraid
®
, Robert De Levie, Washington DC) on Excel
®
 (2010, Microsoft
®
), with the code 
written in visual basic developer (VBA).
88
 Parameter uncertainties were calculated based on the 
partial differentials and matrix inversion method.
88
 The approach for uncertainty estimation is 
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based on an assumption that the uncertainties in data pairs (x, yexp) are found in the dependent 
variable (yexp) and that the uncertainties follow a Gaussian distribution.
88
 Uncertainties in 
parameter estimates were calculated using Equation 22 through Equation 24. In the equations 
below, N is the number of data pairs, P is the number of estimated parameters, and 𝑚𝑖𝑖
−1 denotes 
the i
th
 diagonal term of the inverse of a P × P matrix, the partial differentials of the fitting 
function 
𝑑𝐹𝑛
𝑑𝑎𝑖
 ,where, 𝐹𝑛 = 𝑦𝑐𝑎𝑙𝑐 and 𝑎 is denoting the parameter to be estimated.    
  𝝈𝒊 =  √
𝒎𝒊𝒊−𝟏×(𝒚𝒆𝒙𝒑−𝒚𝒄𝒂𝒍𝒄)
𝟐
𝑵−𝑷
     
Equation 22 
  𝒎𝒊𝒋 =  ∑
𝒅𝑭𝒏
𝒅𝒂𝒊
𝑵
𝒏=𝟏 ×
𝒅𝑭𝒏
𝒅𝒂𝒋
   Equation 23 
  
𝒅𝑭𝒏
𝒅𝒂𝒊
=  𝐥𝐢𝐦∆𝒂𝒊→𝟎
𝒅𝑭𝒏
𝒅𝒂𝒊
=  
𝑭𝒏(𝒙𝒏𝒂𝒊(𝟏+𝜹),𝒅𝒋≠𝒊)−𝑭𝒏(𝒙𝒏𝒂𝒊,𝒅𝒋≠𝒊)
𝒂𝒊(𝟏+𝜹)− 𝒂𝒊
  , 𝜹 ≪ 𝟏    Equation 24 
 
3.3.  Results and Discussion 
The moisture content (% w/w) of the excipients equilibrated under low humidity (5% RH) 
conditions is reported in Table 13. The moisture content of the excipients was recorded to be less 
than 1% w/w in most cases except starch, which had a moisture content value of  
2.69 ±0.28% w/w and HPC with a moisture content value of 1.97 ±0.38% w/w. The relatively 
higher moisture content of the two excipients is due to their inherently high water absorption 
capacities.  
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Table 13: Mean moisture content (±Standard Deviation) of the excipients before physical 
mixing. 
No.      Excipient Moisture Content (% w/w) (n = 2) 
1 Mono-Tab 0.01 ±0.0007 
   
2 talc 0.04 ±0.0007 
   
3 Emcompress
®
 0.22 ±0.0141 
   
4 A-Tab
®
 0.25 ±0.0353 
   
5 HPMC 0.44 ±0.2899 
   
6 Tri-Tab
®
 0.95 ±0.1272 
   
7 HPC 1.97 ±0.3818 
   
8 starch 2.69 ±0.2828 
 
Optical images of the physical mixtures helped identify the effect of excipient particle size on the 
distribution of excipient particles around the gabapentin particles. Images of the single 
component particles (13A-20A) helped in their identification in the binary mixture. Optical 
images for the physical mixtures of gabapentin and the excipients controlled for their particle 
size (125-250 µm) are visualized in Figures 13B-16B. In the case of physical mixtures of 
gabapentin with excipients of smaller particle size (75-125 µm) (Figure 18B-20B), a greater 
number of excipient particles relative to gabapentin particles were observed. This observation 
indicated, greater number of contact points between gabapentin and the excipient relative to the 
contact points between gabapentin and larger sized excipient particles. In the case of talc 
particles (Figure 17B) with the lowest particle size (<3 µm) amongst the excipients, the 
adherence of fine talc particles on the surface of gabapentin was seen, indicating a likelihood of 
greater surface contact between the two components. These observations suggested a need to 
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account for the particle size of gabapentin and the excipients when understanding the effect of 
the excipients on the degradation of gabapentin. 
 
Figure 12: Image representing the morphology of a gabapentin particle under 10x 
magnification. 
 
                              
 
Figure 13: Images representing the morphology of A. starch particles under 10x 
magnification, and B. the physical mixture of gabapentin and starch particles under 4x 
magnification. 
 
                              
Figure 14: Images representing the morphology of A. HPMC particles under 10x 
magnification, and B. the physical mixture of gabapentin and HPMC particles under 4x 
magnification. 
A B 
A B 
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Figure 15: Images representing the morphology of A. Emcompress
®
 particles under 10x 
magnification, and B. the physical mixture of gabapentin and Emcompress
®
 particles 
under 4x magnification. 
 
                                    
Figure 16: Images representing the morphology of A. HPC particles under 4x 
magnification, and B. the physical mixture of gabapentin and HPC particles under 4x 
magnification. 
 
                                     
Figure 17: Images representing the morphology of A. talc particles under 500x 
magnification, and B. the physical mixture of gabapentin and talc particles under 4x 
magnification. The adherence of fine talc particles on the surface of rectangular gabapentin 
particles is observed. 
 
A  B
   
A B 
A B 
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Figure 18: Images representing the morphology of Mono-Tab particles under 10x 
magnification, and B. the physical mixture of gabapentin and Mono-Tab particles under 4x 
magnification. 
 
                              
 
Figure 19: Images representing the morphology of A-Tab
®
 particles under 10x 
magnification, and B. the physical mixture of gabapentin and A-Tab
®
 particles under 4x 
magnification. 
 
                              
 
Figure 20: Images representing the morphology of Tri-Tab
®
 particles under 10x 
magnification, and B. the physical mixture of gabapentin and Tri-Tab
®
 particles under 4x 
magnifications. 
A B 
A B 
A B 
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The results of the study to test the effect of excipients on gabapentin’s degradation strongly 
suggested a role of the excipients on solid-state degradation of gabapentin, as seen in Figures 21 
and 22. A significant (95% confidence interval, n = 3) increase in lactam formation over the 
entire study duration can be seen in the physical mixtures of gabapentin with each of the 
excipients relative to lactam formation in their absence. Two different shapes for the lactam 
formation profile were observed, which varied with the type of excipient used. Amongst the 
physical mixtures, the gabapentin-Tri-Tab
®
 mixture demonstrated the highest lactam formation 
at 697 h, followed in relative order by the mixtures of gabapentin with A-Tab
®
, starch, Mono-
Tab, Emcompress
®
, Talc, HPC, and HPMC.  However, it is important to note the shape of each 
degradation profile. It can be seen in Figure 21, that binary mixtures of gabapentin with 
excipients Tri-Tab
®
, A-Tab
®
, Emcompress
®
, talc, HPMC, and HPC have a similar degradation 
profile. In these profiles, a significant increase in the initial rate of lactam formation (<192 h) is 
observed relative to the degradation profile for gabapentin. However, no distinct rise in lactam 
concentration over time, representative of the branching/ termination phase was seen. The other 
profile for lactam formation is shown in Figure 22, observed for gabapentin and the physical 
mixtures of gabapentin with Mono-Tab and starch. These lactam formation profiles 
demonstrated a lower initial rate of lactam formation relative to other excipients in the study. 
However, a distinct branching phase is seen in their degradation profiles. 
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Figure 21: Effect of the excipients on the solid-state degradation of gabapentin I. Mean 
lactam formation (% mole) across time (h) for gabapentin excipient physical mixtures. 
Degradation profiles represent significant (95% C.I., n = 3) an accelerated lactam 
formation in the presence of excipients relative to gabapentin. Curves represent accelerated 
initial rate of lactam formation (<192 h) but the absence of a distinct branching phase in 
the degradation kinetics.  
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Figure 22: Effect of the excipients on the solid-state degradation of gabapentin II. Mean 
lactam formation (% mole) across time (h) for the gabapentin excipient physical mixtures. 
Degradation profiles represent significant (95% C.I., n = 3) accelerated lactam formation 
in the presence of excipients relative to gabapentin. The excipients did not affect the initial 
rate of lactam (<192 h) formation as much as the other excipients in Figure 21. The 
degradation profile clearly showed a distinct branching phase (>200 h) in the degradation 
kinetics. 
 
To attribute the observed accelerated lactam formation solely to the presence of the excipients, it 
was important to negate the role of the mixing procedure on gabapentin’s degradation. This 
experiment was performed to see if the mechanical shear experienced by gabapentin was not a 
major contributor to the accelerated lactam formation. The results as seen in Figure 23, 
demonstrate no significant (95% confidence interval, n = 3) change in the rate of lactam 
formation across all time points for the gabapentin samples on application of the mixing 
procedure.  
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Figure 23: Effect of the mixing procedure on the solid-state degradation of gabapentin. The 
mean lactam concentration (% mole, n = 3) over time (h) for samples of unprocessed 
gabapentin in the presence and absence of simple mixing protocol. The error bars 
represent a 95% confidence interval. No significant difference between lactam formation 
across all time points is observed on the application of the mixing procedure. 
 
Another factor that needed investigation, before attributing the observed accelerated lactam 
formation to the presence of the excipients, was the moisture content of the excipient. The results 
as seen in Figure 24, demonstrate no significant difference (95% confidence interval, n = 3) in 
lactam formation until 697 h for the physical mixtures of gabapentin and Mono-Tab with 
variable moisture content (0.01% w/w and 1% w/w). A moisture content of 1% w/w in the case 
of Mono-Tab was selected to match the moisture content (0.95% w/w) of Tri-Tab
®
 since Tri-
Tab
®
 was the inorganic excipient demonstrating the highest effect amongst the excipients on the 
rate of lactam formation. The moisture-induced stabilization of gabapentin molecules was not 
observed in the case of the mixtures of gabapentin with Mono-Tab since the physical mixture 
with the higher moisture content showed greater lactam formation. However, to confirm absence 
of an accelerating effect on lactam formation as seen at 697h in Figure 24, further investigation 
(collection of stability data points between 296-697 h) will have to be performed in case of 
Mono-Tab. 
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Figure 24: Effect of varying moisture content in Mono-Tab on the solid-state degradation 
of gabapentin. The mean lactam concentration (% mole, n = 3) over time (h) for samples of 
the gabapentin-Mono-Tab physical mixtures with variable moisture content. The error 
bars represent a 95% confidence interval. 
 
 
In the second study with HPMC, despite variable moisture content (6.66% w/w and  
2.21% w/w) in the HPMC samples, no significant (95% confidence interval, n = 3) difference 
between the degradation profiles of gabapentin and HPMC with variable moisture content was 
observed (Figure 25). This finding negated the role of excipient moisture in accelerating the 
degradation kinetics, which was thought to be a possibility in the case of the gabapentin-Mono-
Tab physical mixtures as discussed above. 
The results from the above studies confirmed the absence of a stabilizing effect of excipient 
moisture on the degradation kinetics of gabapentin, especially in case of HPMC and Mono-Tab. 
Based on the above results, the likelihood of excipient moisture content affecting the degradation 
kinetics of unprocessed gabapentin seems less likely.  
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Figure 25: The effect of varying moisture content in HPMC on the solid-state degradation 
of gabapentin. The mean lactam concentration (% mole, n = 3) over time (h) for samples of 
the gabapentin-HPMC physical mixtures. HPMC, possessed variable moisture content of  
6.66% w/w at 85% RH and 2.21% w/w at 33% RH.  The error bars represent a 95% 
confidence interval. 
 
Application of the Kinetic Model to the Observed Lactam Profiles 
To apply the existing kinetic model to the data and estimate rate constants, the first step involved 
development of an Excel
®
 worksheet to solve the series of differential equations using the 
Runge-Kutta approximation. The Excel
®
 worksheet developed was successfully validated using 
the ode45 function handle on MATLAB
®
. A comparison of the observed data with the predicted 
degradation profile approximated by the MATLAB
®
 routine and the Excel
®
 spreadsheet can be 
seen in Figure 26.  
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Figure 26: Comparison of approximated lactam content (% mole) using the Runge-Kutta 
method on Excel
®
 and Matlab
®
 routine relative to the observed lactam content (% mole) 
over time for the gabapentin-excipient compact stored under accelerated temperature (50 
°C) and humidity conditions (5% RH). 
 
The next step involved use of the Solver function in Excel
® 
to optimize rate constants and initial 
concentration of reactive molecules (gaba0
*
), describing the degradation kinetics of gabapentin. 
First optimization of the rate constants was performed on the data for unprocessed gabapentin by 
fixing a lower value of gaba0
*
. The value of gaba0* was selected to be ~0.027 which was 
substantially lower than the value (0.46% mole) of gaba0* published previously
1
 (by a separate 
research group) for milled (15 min using ball mill at speed 5) gabapentin samples in the absence 
of excipients. The lower value (0.027% mole.) of gaba0
*
 was selected than that published 
previously since a greater concentration of reactive molecules in an unprocessed gabapentin 
sample was less likely. The results as shown in Figure 27 and Table 14 for unprocessed 
gabapentin (red unfilled squares)   demonstrate a good fit between the data predicted by the 
model and the experimentally observed data. The optimized rate constant values for gabapentin 
data were also similar to those published previously.
1
 However, when the same lower value of 
gaba0
*
 was fixed to estimate the rate constants in the case of gabapentin- Tri-Tab
®
 mixture 
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(Figure 27: navy blue triangles) the model-predicted curve failed to provide a reasonable fit 
resulting in a high SSE value, as shown in Figure 27 (green dashed line). A poor fit was obtained 
irrespective of altering all the other rate constants in the model. This observation is due to greater 
initial lactam formation (>0.7% mole at 200h) in the case of the gabapentin-Tri-Tab
®
 physical 
mixture relative to gabapentin (>0.02% mole at 200 h). As per the assumptions of the kinetic 
model, the initial lactam formation is described predominantly by rate constant k2 and the 
concentration of gaba0
*
. Thus a noticeably higher concentration of lactam in the case of the 
gabapentin-Tri-Tab
®
 physical mixture suggests a higher concentration of gaba0
*
 present 
inherently in the gabapentin sample used for the degradation study. 
 
When Excel
®
 solver was allowed to optimize all of the rate constants and the value for gaba0
*
 for 
the gabapentin-Tri-Tab
®
 mixture data, the optimized value for gaba0
*
 was ~3% mole. The 
predicted lactam profile provided a good fit with the observed lactam concentration-time profile, 
as seen in Figure 27 (navy blue dashed line). However, the estimated value of gaba0
*
 was far 
greater than that reported previously.  
 
The next step was to ascertain if the higher value of gaba0
*
 was able to predict the lactam 
concentration for the gabapentin data published in the literature. Based on the published 
literature values of the rate constants (Equations 4-6), a concentration-time profile for lactam 
formation was generated (simulated) as seen in Figure 28 and Table 15. The estimated value for 
the rate constants and higher value of gaba0
* 
were used to generate a lactam formation profile as 
seen in Table 15 and Figure 28. Despite a higher value of gaba0
*
, the predicted profile closely 
matched the simulated lactam profile with a low (0.00009) SSE value. However, it is important 
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to note the value of k2 in Table 15 changed significantly with the change in the value of gaba0
*
. 
This observation is due to the correlation of the two parameters defining the initial rate of lactam 
formation, as seen in Equation 3. 
                
Figure 27: Optimization of the parameters in gabapentin and the gabapentin-Tri-Tab
®
 
physical mixture. The observed lactam concentration-time profiles for gabapentin (red 
squares) and the gabapentin-Tri-Tab
®
 physical mixture (blue triangles) are compared to 
the model-predicted lactam profiles represented by dashed lines. The dashed line for the 
gabapentin-Tri-Tab
®
 model predicted data demonstrates the model predictions at higher 
(blue lines) and lower value (green lines) of gaba0
*
 respectively. 
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Table 14: The model estimated parameters for the gabapentin and gabapentin-Tri-Tab
®
 
physical mixture. A poor curve fit of model-predicted data is observed for the gabapentin-
Tri-Tab
®
 physical mixture after fixing for lower values of gaba0
*
.  
 
Parameter 
Gabapentin 
Fixing gaba0
*
 at 
0.027 and 
Optimizing Other 
Parameters 
Tri-Tab
®
 
Fixing gaba0
*
 at 0.027 and 
Optimizing Other 
Parameters 
Tri-Tab
®
 
Model 
Estimated 
Data 
k1 (mol
-1
h
-1
) 6.8x10
-5
 5.9x10
-5
 1.4x10
-6
 
k2 (h
-1
) 2.5x10
-4
 0.64 1.5x10
-3
 
k3 (mol
-1
h
-1
) 1.0x10
-12
 1.0x10
-8
 1.0x10
-8
 
gaba0
*
(% mole) 0.027 0.027 3.000 
SSE 3.80x10
-6
 3.39 3.60x10
-3
 
 
 
 
Figure 28: Comparison of simulated and predicted lactam concentration-time profiles for 
gabapentin, stored under accelerated temperature (50°C) and humidity (5% RH) 
conditions. The simulated lactam profile is generated using the literature-reported rate 
constants for gabapentin.
1
 The predicted lactam profile is generated using new parameter 
estimates with estimated gaba0
*
 greater than that reported previously.  
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Table 15: The model-estimated parameter values for unprocessed gabapentin relative to 
the previously estimated model parameters. No major alteration in the curve fit was 
observed post-application of new parameter estimates with a greater value of gaba0
*
. 
Parameter 
Simulated Data 
with Previously Published 
Parameter Estimates
1
 
Predicted data 
With New Parameter Estimates 
k1 6.0x10
-5
 7.5x10
-5
 
k2 1.5x10
-2
 5.1x10
-5
 
k3 7.6x10
-5
 3.8x10
-5
 
gaba0
*
 0.027 3.30 
SSE NA 9.0x10
-5
 
 
To confirm that a true solution was obtained after parameterization of the gabapentin-Tri-Tab
®
 
data, non-linear regression was performed using 25 different sets of input values. The parameter 
optimization resulted in an estimate of gaba0* that was 3% mole.  
 
A clear increase in the sum of square error value and a poor fit of the model-predicted data was 
observed when the value of gaba0
*
 was fixed below 3%  mole in the gabapentin-Tri-Tab
®
 data. A 
poor fit was obtained even after the alteration of other parameters, as seen in table 16.  
 
Gaba0* was redefined as the combination of surface molecules and disordered molecules in the 
bulk of the gabapentin crystal. Based on the results obtained for the gabapentin-Tri-Tab
®
 data, 
constraint on the value of gaba0
*
 was set up to not be less than 3% mole. This constraint was 
established when assessing profiles for other gabapentin-excipient mixtures since, in 
unprocessed binary mixtures of gabapentin concentration of gaba0* was not expected to change. 
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The change in the concentration of gaba0
*
 is not expected since it represents the inherently 
present reactive molecules in the gabapentin sample used in the study. 
Table 16:Parameter estimates for the gabapentin-Tri-Tab
®
 physical mixture, post-fixing 
for different values of gaba0
*
.The table demonstrates an increase in the sum of square error 
(SSE) value for the model-predicted fit after fixing for the value of  gaba0
*
 below 3% mole. 
Parameter Input Value 
Optimized 
Output Estimate 
k1 1.4x10
-6
 6.7x10
-6
 
k2 0.0014 0.0022 
k3 1.0x10
-8
 1.0x10
-8
 
Fixed gaba0
*
 2.00 2.00 
SSE 1.270 0.009 
   k1 1.4x10
-6
 9.0x10
-6
 
k2 0.0014 0.0032 
k3 1.0x10
-8
 1.0x10
-8
 
Fixed gaba0
*
 1.50 1.50 
SSE 4.480 0.010 
   k1 1.4x10
-6
 1.5x10
-5
 
k2 0.0014 0.0050 
k3 1.0x10
-8
 1.0x10
-8
 
Fixed gaba0
*
 1.00 1.00 
SSE 1.073 0.045 
   k1 1.4x10
-6
 2.2x10
-5
 
k2 0.0014 0.0190 
k3 1.0x10
-8
 1.0x10
-8
 
Fixed gaba0
*
 0.5 0.5 
SSE 6.818 0.180 
 
The kinetic model for the solid-state degradation of gabapentin was successfully applied to the 
data and a good correlation between predicted and measured lactam concentration was observed, 
with a low sum of square error (SSE <0.001) value across all gabapentin-excipient mixtures, as 
seen in Table 16 and Figure 29. As can be seen from the Figure 29, a higher value (3% mole) of 
gaba0
* 
was able to provide good model fits to all of the gabapentin-excipient mixture data unlike 
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a lower value (<2% mole) of gaba0
*
, which only fit a few gabapentin-excipient mixture profiles. 
Thus the primary reason for a noticeable difference in the magnitude of the estimated value of 
gaba0
*
 between the previously published study
1
, and presented research could be due to the 
initial development of the existing kinetic model only with processed gabapentin in the absence 
of excipients. The model assumed no catalytic effect of the excipient on the rate constant k2.  Rate 
constant k2 and gaba0
*
 are responsible for the rate of initial lactam formation, hence a change in 
k2 value would impact the estimated value of gaba0
*
 from that reported previously.  
 
Figure 29: A comparison between observed and model predicted lactam formation in 
gabapentin and its physical mixture with excipients. Observed lactam concentration is 
indicated by legends, while the dashed lines indicate model predicted fit. The error bars 
represent a 95% confidence interval for three replicates across all time points. The above 
data suggests a good fit between the data predicted by the model and the observed values of 
lactam concentration. 
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After assessing the differential equations, (Equations 1-3), two parameters k2 and gaba0
*
 seem to 
be correlated. The correlation made it difficult to optimize the independent estimate values for 
the two parameters with great precision. Thus, to increase certainty in estimation of rate constant 
k2 the value for gaba0
*
 was fixed at 3% mole and estimates for other rate constants were 
obtained. Rate constants estimated for the data associated with gabapentin-excipient physical 
mixtures is reported in Table 17. The table also provides values of SSE and coefficient of 
determination (R
2
) between the observed and the model predicted lactam concentration values.  
 
 
 
 
8
2
 
 
 
 
 
Table 17: Summary of Optimized Rate Constants for the Degradation of Gabapentin with the Excipients 
Constant Tri-Tab
®
 A-Tab
®
 talc Emcompress
®
 HPC HPMC Mono-Tab starch 
no 
excipient 
k1 
1.4x10
-6
 
±9.7x10
-8*
 
1.0x10
-8
 
±1.2x10
-7*
 
1.4x10
-4
 
±1.7x10
-7*
 
1.2x10
-4
 
±9.5x10
-7*
 
7.3x10
-5
 
±1.5x10
-6*
 
8.6x10
-5
 
±7.4x10
-6*
 
1.2x10
-4
 
±3.1x10
-5*
 
1.2x10
-4
 
±1.3x10
-5*
 
7.7x10
-5        
±4.5x10
-4*
 
k2 
1.4x10
-3
 
±9.4x10
-7*
 
1.3x10
-3
 
±9.4x10
-7*
 
1.0x10
-3
 
±1.1x10
-6*
 
3.5x10
-4
 
±4.3x10
-7*
 
2.2x10
-4
 
±3.1x10
-7*
 
1.1x10
-4
 
±2.8x10
-7*
 
6.9x10
-5     
±3.9x10
-7*
 
6.5x10
-5     
±1.3x10
-7*
 
7.2x10
-6        
±1.0x10
-7*
 
k3 
1.0x10
-8 
±1.4x10
-7*
 
5.5x10
-6 
±1.8x10
-7*
 
2.3x10
-4 
±3.0x10
-7*
 
1.3x10
-4 
±1.0x10
-6*
 
8.4x10
-5 
±1.6x10
-6*
 
7.3x10
-5 
±7.6x10
-6*
 
6.7x10
-5 
±3.2x10
-5*
 
5.8x10
-5 
±1.3x10
-5*
 
1.4x10
-5 
±4.5x10
-4*
 
gaba0
*
 3 3 3 3 3 3 3 3 3 
SSE 0.0036 0.0035 0.0005 0.0009 0.0004 0.0007 0.0108 0.0018 0.0005 
R
2
 0.9990 0.9980 0.9980 0.9980 0.9920 0.9940 0.9920 0.9980 0.9680 
* Estimated standard error using partial differentials and matrix inversion method
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The presence of excipients in the physical mixtures with gabapentin resulted in an increased 
value of the rate constant, k2 (h
-1
), as seen in Figure 30. The highest value for k2 (0.00149 h
-1
) 
was obtained in the gabapentin-Tri-Tab
®
 mixture, while the lowest value for k2 (6.39x10
-5 
h
-1
) 
was obtained for starch. The magnitude of k2 in the absence of excipients was significantly lower 
(7.20x10
-6  
h
-1
) than that in presence of excipients, strongly suggesting that excipients had a 
catalytic effect on lactam formation. 
 
Figure 30: Estimated value for the rate constant k2 across the gabapentin-excipient physical 
mixtures. Up to a 200-times increase in the value of the rate constant is observed for the 
gabapentin-Tri-Tab
®
 mixture relative to its value in the absence of excipients. 
 
The rate constant k1, associated with autocatalytic branching, was estimated to be  
7.75x10
-5
 mol
-1
h
-1 
in case of unprocessed gabapentin as seen in Figure 31.  This estimate was 
similar to the value of k1 (7.1x10
-5
 mol
-1
h
-1
) reported in the literature.
1
 In the presence of 
excipients, the estimated value of the rate constant k1 was 8.45x10
-5
±0.000053 mol
-1
h
-1
. 
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The value of the rate constant k3 which was responsible for reaction termination was  
7.45x10
-5
±0.000073 mol
-1
h
-1
 across gabapentin and the gabapentin-excipient mixtures, as seen in 
Figure 32.  
 
Although the rate constants k1 and k3 did not change significantly in the presence of most 
excipients, much lower values were estimated for the mixtures of gabapentin with Tri-Tab
®
 and 
A-Tab
®
 (Figures 31 and 32). This effect was possibly due to the significantly higher magnitude 
of the rate constant k2, which could be potentially masking the impact of the other two rate 
constants (k1 and k3) in the degradation profiles of gabapentin with Tri-Tab
®
 and A-Tab
®
.  
Lactam profiles for Tri-Tab
®
 and A-Tab
®
 do not display the characteristic acceleration 
associated with the autocatalytic branching phase defined by the current model (Figure 22). On 
the other hand, the autocatalytic phase is seen distinctly in gabapentin and its physical mixtures 
with starch and Mono-Tab, with lower estimated values of the rate constant k2. It is observed that 
as the initial rate of lactam formation (<192 h) increases, branching phase starts to get less 
prominent as seen in Figure 21, which possibly makes estimation of the rate constants k1 and k3 
difficult. 
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Figure 31: Estimated values for the rate constant k1 (mol
-1
h
-1
) across the gabapentin-
excipient physical mixtures. The significantly lower value of k1 in the case of A-Tab
®
 and 
Tri-Tab
®
, is thought to be due to the higher magnitude of k2 masking the actual 
branching/termination phase (described by k1) in the degradation kinetics of gabapentin. 
 
         
 
Figure 32: Estimated values for the rate constant k3 (mol
-1
h
-1
) from the lactam 
concentration time profiles for the gabapentin-Excipient physical mixtures. The 
significantly lower value of k3 in the case of A-Tab
®
 and Tri-Tab
®
, is thought to be due to 
higher magnitude of k2 masking the actual branching/termination phase (described by k3)  
in the degradation kinetics of gabapentin. 
. 
0
0.00002
0.00004
0.00006
0.00008
0.0001
0.00012
0.00014
0.00016
k 1
 m
o
l-1
h
-1
 
0
0.00005
0.0001
0.00015
0.0002
0.00025
k 3
 (
m
o
l-1
h
-1
) 
 
 
86 
 
3.4. Conclusion 
The major objective of this chapter was to provide evidence for the effect of excipients on the 
solid-state degradation of gabapentin. The objective was accomplished, when clear impact of the 
excipients on the solid-state degradation of gabapentin was confirmed in unprocessed powder 
mixtures. The method for preparation of the powder mixtures and the initial excipient moisture 
content were not found to affect the lactamization kinetics. 
 
The central hypothesis of the research was that the physicochemical properties of the 
excipients will accelerate the solid-state degradation of gabapentin, increasing the rate 
constant for lactam formation (k2). The degradation kinetics, predominantly the initial rate 
of lactam formation, will be further accelerated by compaction of the gabapentin-excipient 
physical mixtures. 
 
The results from this chapter proved the hypothesis that conversion of reactive gabapentin to 
lactam driven by the rate constant k2 was affected greatly by the presence of excipients. The 
magnitude of the rate constant k2 was almost 200-times higher in the case of the gabapentin-Tri-
Tab
®
 physical mixture relative to its value for gabapentin. A possible reason for this effect could 
be general base catalysis in solid-state catalyzed by basic materials like Tri-Tab
®
. However, the 
subsequent chapter (Chapter 4) will focus on understanding the role of excipient properties 
responsible for the increased value of rate constant (k2) catalyzed by the excipients. The Rate 
constants k3 and k1, responsible for autocatalytic branching and the branching termination steps 
in the kinetic scheme were less affected in the presence of most excipients.  
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The value of gaba0* was estimated to be around 3% mole which included the surface molecules 
and other disordered molecules in the gabapentin crystal. The estimated value was found to be 
higher than that reported in the literature for the degradation of gabapentin. Further studies will 
have to be carried out to confirm and justify the unexpectedly greater value of gaba0
*
.  
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Chapter 4 
Expansion of the Kinetic Model of Gabapentin Degradation to Account for 
the Physicochemical Properties of Excipients 
 
4.1. Introduction 
In chapter 3, the accelerated degradation of unprocessed gabapentin in the presence of excipients 
was studied. This chapter will focus on understanding the impact of excipient concentration, and 
excipient particle size on the degradation of gabapentin.  
 
The observation of accelerated degradation of gabapentin in the presence of excipients prompted 
modification of the existing kinetic model to account for the presence of excipients. To expand 
the model and incorporate the excipient effect, it was important to confirm the catalytic effect of 
excipient concentration on degradation kinetics. 
 
One of the critical aims of this chapter will be the expansion of the kinetic model to account for 
the excipient effect. The aim is to establish a relationship between the physical properties of 
excipients, such as particle size, particle shape, density, specific surface area and molecular cross 
sectional area, with the rate constant for lactam formation.  
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4.2. Materials and Methods 
4.2.1. Materials 
The materials used in the study are similar to those used in chapter three. However this chapter 
mainly focuses on the impact of excipient (A-Tab
®
) mass and particle size on the degradation of 
gabapentin. The physical properties of calcium phosphate dibasic dihydrate (Emcompress
®
, E. 
Mendell. Co. Inc, New York), monobasic calcium phosphate (V-90 grade, Innophos, New 
Jersey), dibasic calcium phosphate anhydrous (A-Tab
®
, Innophos, New Jersey), tribasic calcium 
phosphate anhydrous (Tri-Tab
®
, Innophos, New Jersey), modified corn starch (Uni-pure
TM
 DW, 
National Starch LLC, New Jersey), hydroxypropyl cellulose (HPC, Klucel EF
®
, Ashland 
Aqualon Functional Ingredients., Delaware), hydroxypropyl methyl cellulose (HPMC, 
Methocel
TM
 E50 Prem LV, The Dow Chemical Co., Michigan) and talcum (Talc, Fisher 
Scientific, Massachusetts) were measured. All other reagents and solvents used for the analytical 
quantitation were HPLC grade.  
 
4.2.2. Study Designs 
The particle size fractions of gabapentin and the excipients were obtained by sieve classification 
using a set of standard sieves (Gilson Company, Inc.) and a sieve shaker (Performer III Model 
SS-3, Gilson Company, Inc.) as described in chapter 3. The particle size fractions of A-Tab
®
  
(75-125 µm, 125-250 µm, 250-500 µm) were separated to study the effect of surface contact 
between gabapentin and the excipient on gabapentin’s degradation 
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Gabapentin was maintained under controlled conditions of temperature (20°C ±2°C) and 
humidity (33% RH, magnesium chloride) for a week prior to the studies due to its higher 
stability under these conditions. The excipients were stored under controlled conditions of 
temperature (50 °C) and humidity (5% RH, Drierite
®
) for at least one week prior to the study to 
ensure a minimal confounding effect of excipient moisture content on gabapentin’s degradation. 
 
To confirm the catalytic effect of excipient mass in the binary mixture, gabapentin was 
physically mixed (n = 3) with different concentrations (5%, 20%, 35%, 50% w/w) of A-Tab
®
 
controlled for their size (125-250 µm). Concentrations of excipient greater than 50% w/w were 
not considered for the study since gabapentin is a low potency drug, commercially available as 
tablets in a 600-800 mg dose. Hence, the concentration of excipients greater than 50% in a 
gabapentin formulation is less likely.   
 
Assuming the catalytic effect of the excipients follows the Law of Mass Action, the rate constant 
for degradation should be proportional to the number of excipient molecules in contact with 
gabapentin molecules. Accordingly, it was hypothesized that increasing the particle size of the 
excipients would decrease the rate constant for lactam formation by decreasing the number of 
surface molecules available for interaction. To test this hypothesis and understand the effect of 
the contact area between gabapentin and excipient particles, physical mixtures of gabapentin and 
different particle size fractions (75-125 µm, 125-250 µm and 250-500 µm) of A-Tab
®
 were 
prepared in a 1:1 proportion by weight. 
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All of the above physical mixtures were stored in scintillation vials (20 ml) under controlled 
conditions of temperature (50 °C) and humidity (5% RH) for the entire study duration (697 h). 
Samples (n = 3) of the mixtures were withdrawn periodically for quantitation of gabapentin and 
its degradation product lactam. Deionized and filtered (0.45 µm sized filter) water was used to 
prepare the samples. The samples were filtered using a 0.45 µm nylon syringe filter and analyzed 
using a validated analytical method as discussed in chapter 2.  
 
The existing kinetic model for solid-state degradation of gabapentin was applied to the generated 
data.
1
 The Runge-Kutta 4
th
 order numerical approximation method was used to solve the series 
of differential equations (Equations 1-3) defining the kinetic model.
1
 The data collected was 
further parameterized using non-linear regression by applying the least squares approach using 
Excel
®
 Solver (Excel
®
 2010). Constraints on the values of gaba0
*
 and the rate constant k1 and k3 
were set up as discussed in chapter 3. To understand the role of the physical properties of the 
excipients on gabapentin’s degradation, a thorough characterization of the excipient’s physical 
properties, such as particle size (µm), particle shape, true density (g/cm
3
), molecular cross-
sectional area (𝐴𝑥,  m
2
), and specific surface area (𝑆𝐸̅̅ ̅,  m
2
/g), was performed. 
 
4.2.3. Particle Size and Shape Determination  
The varying morphology of gabapentin and the excipients required measurement of the mean 
particle size (Feret diameter) using an optical microscope. Measuring the Feret diameter (cm) 
was especially valuable for materials with a needle shaped or rectangular prismatic morphology.  
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Images of gabapentin and excipient particles (n >>200) were acquired using a light microscope 
(Model BX-51, Olympus, Pennsylvania). The images were visualized under 10x objective for 
most excipients and 50x objective in the case of talc. The images were processed using Image J 
software (U.S. National Institutes of Health, Bethesda, Maryland, version 1.41o), to calculate the 
mean Feret diameter. 
 
An optical microscope was also used to visualize the particle morphology for all excipients and 
measure the dimensions (length and breadth) of rectangular particles. Excipient particles  
(n >>100) were analyzed using the Image J software, to determine particle circularity according 
to Equation 25. 
𝑪𝒊𝒓𝒄𝒖𝒍𝒂𝒓𝒊𝒕𝒚 = 𝟒𝝅 ×  
𝑨𝒓𝒆𝒂 𝒐𝒇 𝒂 𝒑𝒂𝒓𝒕𝒊𝒄𝒍𝒆
𝑷𝒆𝒓𝒊𝒎𝒆𝒕𝒆𝒓 𝒐𝒇 𝒂 𝒑𝒂𝒓𝒕𝒊𝒄𝒍𝒆 𝟐
 Equation 25 
Circularity values typically range from 1 in the case of a perfect circle to 0 in the case of an 
infinitely long polygon. The circularity values helped differentiate the morphology of the 
different materials. 
 
4.2.4. Determination of Molecular Cross-Sectional Area  
To compute the cross-sectional area of the excipient molecule, the 2-dimensional (2-D) chemical 
structure of each excipient was acquired using ChemDraw
®
 software (version 13.0, PerkinElmer. 
Massachusetts). In the case of polymers, the structures of the monomer units were considered for 
the determination of the molecular cross-sectional area. The 2-dimentional chemical structure 
was transformed to a 3-dimensional structure using Molecular Operating Environment (MOE 
2013.08, Chemical Computing Group, Quebec, Canada) software. Energy minimization was 
performed using force field MMF94X and a 0.05 gradient. The van der Waals radii of atoms 
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were taken into account, and the contours of the projections were smoothened using a water 
probe of 1.4 Å radius. The lengths of the major and minor axis of the projected surface in two 
orientations were measured to compute the average cross-sectional area of the molecule 
assuming an ellipsoidal geometry. The computed molecular surface and the axis measured for 
the cross-sectional area determination are depicted in appendix 2.  
 
4.2.5. Specific Surface Area Measurements 
One of the most important physical properties of a material is its specific surface area (𝑆𝐸,̅̅̅̅ , m
2
/g). 
This property becomes especially important when understanding interactions at the drug-
excipient interface. The measurements of specific surface area were made using nitrogen vapor 
adsorption data (FlowSorb II 2300, Micromeritics Instrument Corporation, Georgia) with 
subsequent application of Brauner,Emmett and Teller (BET) model. Helium was employed as 
the carrier gas and liquid nitrogen served as the external coolant. Approximately 1.0-1.5 g of the 
excipient was filled into a clean, dry sample tube. The samples were outgassed for more than  
24 h at higher temperatures (50-200°C) for calcium phosphates (anhydrous grade) and talc. To 
prevent alteration of any physical properties, materials such as dibasic calcium phosphate 
dihydrate, modified corn starch, HPC, and HPMC were outgassed at 50°C for more than 24 h 
and further degassed at 50°C for 5 h. A single sample of each material was analyzed. 
Measurements were conducted at a series of relative pressures (p/p0) of 0.05, 0.10, 0.15, 0.20, 
0.25, and 0.30, and the moles of nitrogen adsorbed (n) at each of the partial pressures was 
analyzed with the BET equation (Equation 26), given below in its linear form. 
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𝑷
𝑷𝟎
𝒏(𝟏 −
𝑷
𝑷𝟎
)
=  
𝟏
𝒄 × 𝒏𝒎
+ 
(𝒄 − 𝟏)
𝑷
𝑷𝟎
𝒄 × 𝒏𝒎
 Equation 26 
Linear regression analysis was used to estimate the moles of nitrogen adsorbed at monolayer 
coverage (nm) and the affinity constant (c). The specific surface area was taken as a quotient of 
the sample’s total surface area and mass. The cross-sectional area of a nitrogen molecule was 
assumed to be 16.2 Å
2 
in all of the calculations. 
 
4.2.6. True Density Measurement 
The true density of the materials was used to estimate the number of excipient and drug particles 
in the mixture considering for their volume and mass. The measurements were also used to 
estimate the solid fraction of gabapentin-excipient compacts, which will also be discussed in 
chapter 5. This measurement uses helium pressure and Boyle’s law (the product of pressure and 
volume is constant for a closed system at a fixed temperature) to calculate the volume occupied 
by powder particles. The true density of each material weighing between 5-10 g was measured in 
triplicates using helium pycnometry (Model: SPY-6DC, Quantachrome Instruments, Boynton 
Beach, Florida). The samples were degassed for 30 min. To determine the effective powder 
density, the volume was normalized by the final powder mass.  
 
4.2.7. Theoretical Estimation of the Fraction Surface Area of the Excipient Particle in 
Contact with Gabapentin Particle 
 
In binary mixtures of gabapentin with excipients, it is expected that a single particle of 
gabapentin will be in contact with multiple particles of excipients and gabapentin. To calculate 
the fraction of excipient surface area in contact with gabapentin, the first step involved 
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estimating the number-fraction of excipient particles and gabapentin particles around a single 
gabapentin particle in the mixture.
89,90
 The Komatsu model
89
 was used for this purpose. This 
model was developed for binary mixtures. It assumes as per Equation 27, the number ratio of the 
individual component particles in the mixture (𝑁𝐴 and 𝑁𝐵) to be equal to the ratio of each 
component particle ( 𝑛𝐴 𝑎𝑛𝑑 𝑛𝐵 ) contacting a single particle in the binary mixture (Equation 
27).
89,90
 
𝒏𝑨
𝒏𝑩
=  
𝑵𝑨
𝑵𝑩
 Equation 27 
Assuming, a binary mixture of two components A and B,  𝑛𝐴 𝑎𝑛𝑑 𝑛𝐵  are the number of particles 
of component A and B in contact with a single particle of component B. 
The total number of individual component particles (𝑁𝐵 𝑎𝑛𝑑 𝑁𝐴 )  in the binary mixture is 
estimated using the molar mass (𝑀𝑤), true density (𝜌) and volume (𝑉) of the individual 
components (Equation 28).
89,90
 
𝑵𝑨
𝑵𝑩
=  
𝑽𝑩 × 𝝆𝑩 × 𝑴𝒘𝑨
𝑽𝑨 × 𝝆𝑨 × 𝑴𝒘𝑩
 Equation 28 
The Komatsu model was used to estimate the total number of individual component particles 
(𝑁𝐵 𝑎𝑛𝑑 𝑁𝐴 ) and the number-fraction of component A (excipient) particles and component B 
(gabapentin) particles around a single particle B (gabapentin) in the binary mixture  
(Equation 29-30).
 89,90
 The volumes of the excipient and gabapentin particles were determined 
based on the morphology, and the dimensions of the particles measured using optical 
microscopy.  
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𝒏𝑨
(𝒏𝑨+𝒏𝑩)
=  
𝑵𝑨
𝑵𝑩
𝟏+
𝑵𝑨
𝑵𝑩
  Equation 29 
𝒏𝑩
(𝒏𝑨+𝒏𝑩)
=  
𝟏
𝟏+
𝑵𝑨
𝑵𝑩
  Equation 30 
The next step involved the use of Equation 31 to estimate the total number of particles (𝑁𝑇)  
(excipient + gabapentin) contacting a single particle of gabapentin. This was calculated using the 
surface area of the gabapentin particle and the contact surface area (CSA) between the excipient 
and gabapentin particles. 
𝑵𝑻 =
𝑺𝒖𝒓𝒇𝒂𝒄𝒆 𝒂𝒓𝒆𝒂 𝒈𝒂𝒃𝒂𝒑𝒆𝒏𝒕𝒊𝒏 𝒑𝒂𝒓𝒕𝒊𝒄𝒍𝒆
(
𝒏𝑨
𝒏 × 𝑪𝑺𝑨 𝒆𝒙𝒄𝒊𝒑𝒊𝒆𝒏𝒕) + (
𝒏𝑩
𝒏 × 𝑪𝑺𝑨 𝒈𝒂𝒃𝒂𝒑𝒆𝒏𝒕𝒊𝒏)
 Equation 31 
 
The surface area of the gabapentin particle was estimated by measuring its dimensions (length 
and breadth) using optical microscopy. The height of the gabapentin particle was assumed to be 
equal to its breadth considering the limitation of 3-D imaging on an optical microscope. The 
cross-sectional area (CSA) of the excipient and gabapentin particles were calculated based on the 
particle morphologies In the case of rectangular particles, two different orientations were 
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Figure 33: Graphical representation of the physical mixture of gabapentin (rectangular 
prismatic) particles (B) with excipient particles (A) of different shapes, I. Spherical or 
nearly spherical excipient particles. II. Rectangular prismatic excipient particles.  
III. Contact area between particles of gabapentin and spherical excipients IV. Contact 
area between particles of gabapentin and rectangular excipients 
I II 
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possible; in these cases the mathematical average of the contact surface area for the two 
orientations were used to estimate the total number of particles, as per Equation 31.  In the case 
of spherical excipient particles in contact with gabapentin, the point of contact would typically 
be a point on the spherical surface contacting gabapentin (Figure 33, I). Since it is difficult to 
measure the area of a point contact, the area of interaction (Van-der-Waals) between a sphere 
and a plane (π x2) was calculated as the particle contact area. The distance x (Figure 33 III) was 
measured using optical microscopy in conjunction with the image J software. The range for PCA 
between the gabapentin and excipient particle with a rectangular prismatic morphology (Figure 
33 II) was calculated using the formula for area of contact between two rectangular bodies 
(length × breadth). The dimensions of excipient particles (rectangular prismatic) were also 
measured using optical microscopy (Fig. 33 IV).
63
 After estimating 𝑁𝑇 as per Equation 31, the 
number of excipient (𝑁𝐸) and gabapentin particle around a single gabapentin particle was 
calculated using Equation 32. 
𝑵𝑬 =  
𝒏𝑨
𝒏
 × 𝑵𝑻 Equation 32 
 
Finally, the fraction surface area (𝒇) of the excipients in contact with gabapentin was calculated 
using Equation 33. This equation helped in calculating the fraction surface area of the excipient 
in contact with gabapentin, accounting for the effects of size, shape, and density of both the 
gabapentin and excipient particles. 
𝒇 =  
𝑵𝑬 × 𝑷𝑪𝑨  (𝒎
𝟐)
𝑺𝒖𝒓𝒇𝒂𝒄𝒆 𝒂𝒓𝒆𝒂 𝒐𝒇 𝒆𝒙𝒄𝒊𝒑𝒊𝒆𝒏𝒕 (𝒎𝟐)
 Equation 33 
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4.3. Results and Discussion 
The results in chapter 3, have demonstrated the impact of excipients on the solid-state 
degradation of gabapentin. The results in Figure 34, strongly suggests an increase in lactam 
formation with an increase in the concentration of the excipient (A-Tab
®
) in the binary mixture 
with gabapentin. This observation supported the hypothesis that excipient molecules play a role 
in the kinetics of gabapentin’s degradation in a concentration-dependent manner. Consequently, 
the existing kinetic model needed modifications to account for the presence of excipients.  
 
 
Figure 34: Effect of excipient concentration on the degradation of gabapentin. The graph 
represents mean lactam concentration (% mole) over time (h) with increasing 
concentration of the A-Tab
®
 in the binary mixture. The error bars represents confidence 
interval (95%) for three replicates. 
 
The results presented in Figure 35 also suggested lactam formation to be inversely proportional 
to the particle size of A-Tab
®
. It was observed that physical mixtures of gabapentin with a 
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smaller particle size fraction (75-125 µm) of A-Tab
®
 showed a greater concentration of lactam  
(1.63% mole at 696 h) relative to the lactam content (1.31% mole and 1.10% mole respectively 
at 696 h) in physical mixtures with larger size fractions (125-250 µm and 250-500 µm) of A-
Tab
® 
. This observation indicated a key role of the surface molecules of excipient in accelerating 
lactam formation. However, a major difference in the specific surface areas of the different size 
fractions of A-Tab
® 
was not observed (Figure 35 inset). This observation indicated that a large 
fraction of A-Tab’s molecules were contained in the pores on the particle surface. The molecules 
within the pores are less likely to be in direct contact with the gabapentin particles. This 
observation highlighted the importance of external surface area in driving the degradation 
kinetics, relative to the overall specific surface area of the material.  
 
 
Figure 35: Effect of excipient particle size on the degradation of gabapentin. (◊) A-Tab
®
  
75-125 µm, (□) A-Tab
®
 125-250 µm, (Δ) A-Tab
®
 250-500 µm. The above data suggests the 
role of the external surface area of excipient on the degradation of gabapentin. 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 100 200 300 400 500 600 700
La
ct
am
 (
%
 m
o
le
) 
Time (h) 
A-Tab 75-125 um
A-Tab 125-250 um
A-Tab 250-500 um
 
 
100 
 
4.3.1. Modification of the Kinetic Model for Degradation of Gabapentin to Incorporate 
the Excipient Effect 
 
The existing kinetic model for the degradation of gabapentin does not account for the catalytic 
effect of the excipient on gabapentin’s degradation. To incorporate the excipient effect, the 
model was modified by the addition of a new, catalyzed pathway between reactive gabapentin 
and gabapentin lactam. The rate constant describing the kinetics of the pathway was denoted as 
k4 (Figure 36). The expansion of the kinetic model resulted in modification of the differential 
equations (Equations 34-38) associated with the model. 
 
 
 
 
𝐝[𝐠𝐚𝐛𝐚]
𝐝𝐭
= −𝒌𝟏[𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂
∗ + 𝑳] + 𝒌𝟑[𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂
∗]       Equation 34      
𝐝[[𝐠𝐚𝐛𝐚∗]
𝐝𝐭
=  𝒌𝟏[𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂
∗ + 𝑳] − 𝒌𝟑[𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂
∗] − 𝒌𝟐[𝒈𝒂𝒃𝒂
∗] −
                     𝒌𝟒 [𝒈𝒂𝒃𝒂
∗][𝐄]  
Equation 35                                            
𝐝[𝐋]
𝐝𝐭
= 𝒌𝟐[𝒈𝒂𝒃𝒂
∗] + 𝒌𝟒 [𝒈𝒂𝒃𝒂
∗][𝐄]  Equation 36        
𝐝[𝐋]
𝐝𝐭
= 𝐠𝐚𝐛𝐚∗ (𝐤𝟐 + 𝐤𝟒𝐄)    Equation 37         
(𝐤𝟐 + 𝐤𝟒𝐄) = 𝒌𝟐
∗       Equation 38        
Figure 36: Expanded kinetic model for the solid-state degradation of gabapentin in the presence 
of excipients. Rate constant k4 was added to the model to represent the rate constant catalyzed by 
the excipient molecules (E). 
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𝒌𝟐
∗  is the newly derived apparent rate constant for the conversion of reactive gabapentin to 
lactam. This rate constant is the sum of both the excipient catalyzed and the uncatalyzed rate 
constants. 𝐸 represents the concentration (% mole) of surface molecules on the excipient 
particle. The concentration of surface molecules on the excipient particle is further described by 
combination of physical properties of the excipients as seen in Equation 39. 
𝑬 =  [
 𝑺𝑬̅̅ ̅ 
𝑨𝒙 × 𝑵𝑨
𝒎𝑬
𝑴𝒘𝑬
+
𝒎𝑮
𝑴𝒘𝑮
× 𝟏𝟎𝟎]  𝒎𝑬 Equation 39 
As seen in Equation 39, 𝑆𝐸̅̅ ̅ (m
2
/g) is the specific surface area of the excipient, 𝐴𝑥 (m
2
/ molecule) 
is the molecular cross-sectional area of the excipients, 𝑁𝐴 (molecules/mole) is Avogadro’s 
number, 𝑚𝐸 (g) is the mass of the excipient, 𝑚𝐺 (g) is the  mass of gabapentin in the physical 
mixture, and 𝑀𝑤 (g/mol.) is the molecular weight of the excipient (𝑀𝑤𝐸) or gabapentin (𝑀𝑤𝐺).  
 
The representation of 𝐸 using the physical properties of the excipients facilitated the 
development of a relationship that accounted for the effect of major physical properties of the 
excipients on the apparent rate constant for lactam formation, as seen in Equation 40. 
𝒌𝟐
∗ =  𝒌𝟐 +  𝒌𝟒 × [
 𝑺𝑬̅̅ ̅ 
𝑨𝒙 × 𝑵𝑨
𝒎𝑬
𝑴𝒘𝑬
+
𝒎𝑮
𝑴𝒘𝑮
× 𝟏𝟎𝟎]  𝒎𝑬 Equation 40 
Where 𝑘2  (h
-1
) is the rate constant for lactam formation in the absence of excipient molecules, 
𝑘4 (h
-1
 mol
-1
) is the excipient catalyzed rate constant for the conversion of gaba* to lactam in the 
presence of excipients.  
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The developed relationship had multiple limitations. First, it assumed the total surface molecules 
of the excipient to be catalyzing the reaction. This assumption is unlikely especially when 
considering simple physical mixtures. Second, the relationship failed to take into account 
important physical properties such as the particle size and shape of both the excipient and the 
gabapentin particle. Third, the above relationship could lead to overestimation of the 
concentration of excipient molecules for catalysis, in the case of porous excipient materials like 
A-Tab
®
, where greater concentration of the molecules would be contained in the pores. 
 
To overcome the above limitations, a factor that could assist in estimating the actual surface area 
of the excipient in contact with gabapentin based on the particle size, shape and density of both 
gabapentin and excipient particles was included in the model. 
 The relationship was modified to include a factor (𝑓), as seen in Equation 41.    
𝒌𝟐
∗ =  𝒌𝟐 +  𝒌𝟒 × 𝒇 × [
 𝑺𝑬̅̅ ̅ 
𝑨𝒙 × 𝑵𝑨
𝒎𝑬
𝑴𝒘𝑬
+
𝒎𝑮
𝑴𝒘𝑮
× 𝟏𝟎𝟎]  𝒎𝑬 Equation 41 
Factor (𝑓) represents the fraction surface area of the excipients in contact with gabapentin. This 
theoretical estimation was based on the principles of the Komatsu model to determine the contact 
area between components in a binary mixture.
89
 
 
Cumulative lists of all the measured physical properties of the excipients are summarized in 
Table 18. The moisture content of the excipients was recorded to be less than 1% w/w for most 
excipients, except starch (2.69 ±0.28% w/w) and HPC (1.97±0.38% w/w) due to their ability to 
absorb greater amounts of moisture.  However, the minimal effect of excipient moisture on the 
degradation kinetics of gabapentin in the unprocessed state was observed in chapter 3. The 
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excipients under study showed wide variations in their surface properties. As seen in Table 18, 
the highest specific surface areas, 54.00 m
2
/g and 22.40 m
2
/g, were recorded for the porous 
excipients Tri-Tab
®
 and A-Tab
®
. Lower porosity materials, such as Mono-Tab and starch, 
demonstrated lower specific surface area values of 0.70 m
2
/g and 0.22 m
2
/g, respectively. The 
molecular cross-sectional area varied between 2.30x10
-19
 m
2
 and 8.60x10
-19
 m
2
 between 
excipients. The highest molecular cross-sectional area was recorded for HPC, while, the lowest 
molecular cross-sectional area was recorded for A-Tab
®
 (Appendix 2). 
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Table 18: Cumulative List for the Various Physical Properties of Excipients 
Excipient 
𝑀𝑤𝐸 
(g/mole) 
 
True 
Density 
(g/cm
3
) 
𝑆𝐸̅̅ ̅ 
(m
2
/g) 
 
𝐴𝑥 
(m
2
/molecule) 
 
Moisture 
Content 
(% w/w) 
Particle 
Dimension
(cm) 
Morphol
ogy 
& 
Circular
ity (C) 
Tri-Tab
®
 502.3 3.11 
(± 
0.004) 
54.54 7.2x10
-19
 0.95 
(± 0.12) 
0.0122
#
 C = 0.77 
A-Tab
®
 136.0 2.92 
(± 
0.009) 
22.41 2.3x10
-19
 0.25 
(± 0.03) 
0.0118
#
 C = 0.68 
 
talc 379.3 2.55 
(± 
0.003) 
9.03 5.8x10
-19
 0.04 
(± 0.00) 
0.000325
#
 C =0.63 
 
Emcompr
ess
®
 
172.1 2.61 
(± 
0.002) 
4.53 2.8x10
-19
 0.22 
(± 0.01) 
0.0153
#
 C = 0.63 
 
HPMC 279.0 1.25 
(± 
0.005) 
0.97 6.1x10
-19
 0.44  
(± 0.08) 
(0.013 
,0.0011, 
0.0011)* 
C = 0.06 
 
Mono-
Tab 
234.0 2.60 
(± 
0.004) 
0.70 4.2x10
-19
 0.01 
(± 0.00) 
(0.016, 
0.0035, 
0035)* 
C = 0.07 
 
HPC 321.0 1.23  
(± 
0.009) 
0.93 8.6x10
-19
 1.97 
(± 0.38) 
(0.0125, 
0.0039, 
0.0039)* 
C = 0.04 
 
starch 164.0 1.44 
(± 
0.003) 
 
0.22 6.7x10
-19
 2.69 
(± 0.28) 
0.0125
#
  C= 0.82 
 
#
 = Mean Feret Diameter for spherical or nearly spherical particle 
* = measured length, breadth of a rectangular prismatic excipient particle. Thickness was 
assumed to be equal to the breadth. 
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The excipients were either spherical (or nearly spherical) or possessed a rectangular prismatic 
geometry. Particles with circularity values above 0.6 were considered to be nearly spherical 
while those below 0.6 were classified as rectangular prismatic. Amongst the spherical excipients, 
the mean Feret diameter recorded was highest in the case of Emcompress
®
 (0.0153 cm) and 
lowest in the case of talc (0.000325 cm). On the other hand in the case of excipients with 
rectangular prismatic geometry two orientations of the molecule contacting gabapentin could be 
imagined. Amongst the excipients, Mono-Tab demonstrated greater particle dimensions  
(l = 0.016 cm and b = 0.0035 cm) relative to the particle dimensions for HPMC (l = 0.0130 cm 
and b = 0.0011 cm) and HPC (l = 0.0125 cm and b = 0.0039 cm).  
 
The total molecular concentration on the surface of the excipient particle, capable of accelerating 
gabapentin’s degradation was calculated and is reported in Table 18. As expected, the specific 
surface area of the excipient particle played a critical role where excipients with greater specific 
surface area values, such as Tri-Tab
®
 and A-Tab
®
 had greater concentrations of total surface 
moles available for interaction. Similarly, excipients with lower specific surface area values, 
such as starch and Mono-Tab displayed a lower concentration of molecules at the surface. 
Amongst the excipients, HPC despite of relatively higher surface area value than Mono-Tab, 
showed a similar concentration of molecules at the surface; this was due to the higher molecular 
cross-sectional area of HPC relative to that of Mono-Tab. It was observed that the molecular 
cross-sectional area and specific surface area of the excipients together played an important role 
in estimating the total surface molar concentration. After addition of the factor (𝑓) to estimate 
the fraction surface area of the excipient particle in contact with gabapentin, a more accurate 
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representation of the concentration of excipient molecules expected to be in contact with 
gabapentin was reported as seen in Table 19.  
 
Table 19: Estimation of surface molar concentration on the excipient particle available for       
catalyzing lactam formation 
Excipients 𝑁𝐸  
Total % Mole 
on Surface of 
Excipient 
Particle 
𝑓  
 
Estimated 
Actual % Mole  
on Excipient 
Particle in 
Contact with 
Gabapentin 
Tri-Tab
®
 0.05 1.339 0.00007 0.00010 
A-Tab
®
  0.06 0.453 0.00026 0.00012 
Emcompress
®
 0.03 0.091 0.00117 0.00010 
talc 859.64 0.155 0.00736 0.00114 
starch 0.10 0.002 0.05377 0.00015 
HPC 0.59 0.012 0.02188 0.00081 
HPMC 4.90 0.019 0.33649 0.00241 
Mono-Tab 0.30 0.013 0.15980 0.00084 
 
The value for (𝑓) (0.02-0.33) was estimated to be higher in the case of particles with a 
rectangular shape relative to the estimated value of (𝑓) (0.00007-0.053) in the case of spherical 
particles. This was due to the greater PCA between two rectangular particles relative to a sphere 
and a rectangular-shaped particle. However, in the case of starch and gabapentin physical 
mixture, the value of (𝑓) (0.053) was higher relative to other spherical excipients due to the 
greater contact surface area (CSA) between gabapentin and starch particles relative to most other 
spherical excipients. Hence the total estimated surface area of starch in contact with gabapentin 
was higher relative to the total available surface area of starch in the mixture.  
 
Talc, despite its spherical shape, had a greater magnitude for (𝑓) relative to other spherical 
particles of excipients due to the smaller particle size of talc relative to other excipients, which 
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resulted in a higher estimated number of talc particles in contact with gabapentin. In the case of 
HPMC, greater numbers of HPMC particles (4.9 particles) were estimated to be covering a 
surface of gabapentin relative to other excipients in the study, which was a result of its higher 
estimated (𝑓) value. The actual surface molecules of the excipients in contact with gabapentin 
were calculated to be greater in the case of talc and HPMC due to the higher estimated value of 
(𝑓) relative to other excipients in the study.  
 
In summary, the theoretically estimated fraction of surface moles in contact with gabapentin was 
found to be dependent mainly on the shape, size, density and molecular weight of the excipient. 
This estimation facilitated calculation of the rate constant k4 using Equation 41 for lactam 
formation in the presence of excipients (Figure 37).    
 
Figure 37: Estimated catalytic rate constant k4 (h
-1
mol
-1
) for lactam formation in the 
presence of excipients. The plot is in logarithmic scale for the y-axis to show the magnitude 
of difference in the effect of excipient type on gabapentin’s degradation. Maximal effect is 
shown by inorganic basic excipients relative to inorganic acidic excipients and polymers. 
0.0001
0.001
0.01
0.1
1
10
100
k
4
 m
o
l-
1
h
-1
 
 
 
108 
 
The estimation of rate constant k4 helps in determining a role of the excipient’s chemical 
properties in catalyzing lactam formation. However, the present data was unable to pinpoint a 
direct connection between the rate constant k4 and a chemical property of the excipient. 
However, the results indicated a greater impact of inorganic salts of basic nature (Tri-Tab
®
 (pKa 
12.12), A-Tab
®
 (pKa 7.4), talc (pKa 9.19), and Emcompress
®
 (pKa 7.4)) relative to inorganic 
excipients of acidic nature (Mono-Tab (pKa 2.12)). Polymers (HPMC, HPC, and starch) had a 
lower impact on the degradation of gabapentin relative to the inorganic excipients. A possibility 
of a general base catalysis similar to that observed in the solution state degradation kinetics of 
gabapentin cannot be ignored. In the case of polymers and organic excipients, it could be 
hypothesized that the presence of impurities of a basic nature could be driving the catalysis of the 
reaction. However, further investigation will have to be planned in order to test this hypothesis. 
Nevertheless, to make a strong conclusion, and relate a particular chemical property of the 
excipients to affect lactam formation, the existing library of excipients will have to be expanded.  
 
Currently, the ability to estimate k4 from the developed relationship helps to facilitate excipient 
selection and the separation of a certain chemical class of excipients capable of catalyzing 
gabapentin’s degradation.  
 
On further validation, the model has the potential to be used as a tool in screening excipients and 
facilitating their selection for solid formulations of gabapentin. The model will enable risk 
assessment and identify formulations exceeding the regulated lactam content upon alterations in 
the physical properties of excipients due to batch-to-batch variation or change in the source for 
excipient procurement. 
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4.4.  Conclusion 
The results confirmed a catalytic effect of the excipient concentration on gabapentin’s 
degradation profile. To account for the effect of excipient properties, the existing kinetic model 
for gabapentin’s degradation was modified, and rate constant k4 for lactam formation in the 
presence of excipients was incorporated. On modification of the kinetic model, the rate constant 
k2
*
 (combination of rate constants k2 and k4) was defined as the “apparent rate constant” that 
accounted for lactam formation in the presence and absence of excipients.  
 
Referring back to the research hypothesis, which stated that physicochemical properties (such 
as specific surface area, molecular weight, particle size, particle shape and, acidic or basic 
strength) of the excipients will accelerate the solid-state degradation of gabapentin, 
increasing the rate constant (k2) for lactam formation. The results from this chapter proved 
the hypothesis and concluded major physical properties of the excipient such as their particle 
size, morphology, specific surface area, molar weight, and molecular cross-sectional area to be 
impacting the rate constant (k2) for lactam formation. However no specific chemical properties 
of the excipients were found to be impacting the lactamization kinetics. 
 
An inverse relationship between the particle size of the excipient and the rate of lactam 
formation was concluded. This finding prompted a strong need to theoretically estimate the 
actual surface moles of the excipient in contact with gabapentin after considering for the effect of 
particle size, shape, and density. Model expansion resulted in the development of a relationship 
between the apparent rate constant (k2
*
) and surface molar concentration of the excipient in 
contact with gabapentin based on the physical properties of the excipients. The proposed 
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relationship has the potential to be used as a tool to assess the effect of different physical and 
chemical properties of the excipient on the solid-state degradation of gabapentin.  
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Chapter 5 
Effect of Compaction and Powder Properties of Excipients on the Solid-State 
Degradation of Gabapentin 
5.1. Introduction 
In chapter 4 we studied the effects of the physical properties of excipients on gabapentin’s 
degradation. We also developed a theoretical model to predict how lactam content changes over 
time as excipient properties change. The results in chapter 4 are based on the physical mixing of 
gabapentin and excipients. Commercially, gabapentin is mainly available as tablets. Hence, it is 
also important to study the effects of compaction.  
 
We hypothesized that in addition to the catalytic effect of excipients, compaction stress will 
accelerate lactam formation. It was expected that in the case of a highly crystalline drug like 
gabapentin, compaction stress would cause crystal damage and increase the concentration of 
reactive gabapentin molecules available for lactam formation. It was also expected that 
compaction in the presence of excipients would accelerate lactam formation by increasing the 
area of contact or the number of points of contact between gabapentin and the excipient 
molecules.   
 
In this chapter we will study the effect of compaction stress, compact porosity, compaction 
energy, yield pressure and moisture content of the excipient as potential factors affecting the 
solid-state degradation of gabapentin. 
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5.2. Materials and Methods 
5.2.1. Materials 
Compacts for the study were prepared using physical mixtures of gabapentin and excipients in a 
1:1 proportion. The excipients used for the study were dibasic calcium phosphate dihydrate 
(Emcompress
®
, E. Mendell. Co. Inc, New York), modified corn starch (Uni-pure
TM
 DW, 
National Starch LLC, New Jersey), hydroxypropyl cellulose (HPC, Klucel EF
®
, Ashland 
Aqualon Functional Ingredients, Delaware), hydroxypropyl methyl cellulose (HPMC, 
Methocel
TM
 E50 Prem LV, The Dow Chemical Co., Michigan) and talcum (Talc, Fisher 
Scientific, Massachusetts). All other reagents and solvents used for the analytical quantitation 
were HPLC grade.  
 
5.2.2. Material Pretreatment 
All solid materials including gabapentin and the excipients were stored under controlled 
conditions of temperature and humidity (21°C and 33% RH) for 1 week prior to compaction. The 
materials were not controlled for their particle size and were used as received from the supplier. 
 
5.2.3. Determination of Moisture Content  
The moisture content (% w/w) of the excipients was determined using thermogravimetric 
analysis (TGA Q-500, TA Instruments, Delaware). The average and standard deviation of two 
replicate measurements has been reported. 
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5.2.4. True Density Determination 
The true density was determined using helium pycnometry (Model: SPY-6DC, Quantachrome 
Instruments, Boynton Beach, Florida) as described in chapter 4 and was performed in triplicates 
for each excipient.  
 
5.2.5. Study Protocol 
Gabapentin and excipients were mixed individually for every compact, in a 1:1 weight ratio  
(200 mg each) in a geometric proportion. Batch mixing of gabapentin with the excipients was 
avoided to eliminate sampling related inhomogeneity issues. In the case of gabapentin without 
excipients, 400 mg of gabapentin was weighed for compaction.  Compacts of the physical 
mixtures (n = 3/time-point) were prepared using Instron Universal Testing System (Model 5869, 
Instron Corporation, Norwood, Massachusetts) at a compaction speed of 240 mm/min to a 
maximum pressure of 36.6 kN, measured using a 50 kN load cell in a 13 mm steel cylindrical 
die. Decompression using the same crosshead speed began immediately after the maximum load 
was reached. Punch separation distance was corrected for deformation of the tooling. This was 
done by adding the displacement measured during compression of the punches in an empty die to 
the punch separation distance measured during formation of each compact. The compact 
thickness and the diameter were measured immediately after ejection from the die using a set of 
digital calipers. Extra compacts for every set of gabapentin-excipient mixtures were prepared in 
triplicate and stored for 4-5 consecutive days under ambient temperature (21°C) and humidity 
conditions (31-33% RH)  to allow for viscoelastic relaxation. This step was important to measure 
the “out of die” thickness of the tablets after the relaxation process in order to calculate the 
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compact porosity. This measurement of the “out of die” thickness was especially critical in the 
case of gabapentin compacts with viscoelastic materials like starch. 
 
Compact porosity was calculated using the mass of the compact and the true density of 
individual components using Equation 42. In the case of physical mixtures, the true density of 
the mixture was calculated as the weighted sum of the true densities of the individual 
components based on their mass ratio. 
𝜺 = 𝟏 −
𝟒𝒎
𝝅 (𝑫)𝟐 𝒕𝝆
 Equation 42 
In the above equation, 𝜀 denotes porosity, 𝑚 is mass of the compact, 𝐷 is the diameter of the 
compact, t is the compact thickness after viscoelastic relaxation, and 𝜌 is the true density of the 
physical mixture. 
 
As discussed in chapter 1, the Heckel model for consolidation was used to calculate the yield 
pressure (𝑃𝑦) of different physical mixtures, as per Equation 21.  
 
The mechanical energy values were determined using the Blue Hill Software Package (Instron, 
Norwood, Massachusetts). The work of compression (Wc) and work of decompression (Wd) 
were determined by integration of the force vs. displacement plots. Work of compression values 
represent the amount of work absorbed by the sample during compression that is not released 
during decompression.  
𝑾𝒄/𝒅 =  𝑾𝒄 +  𝑾𝒅 Equation 43 
In equation 43, 𝑊𝑐/𝑑 represents the irreversible work (J/g) utilized in making the compact. 
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The compacts (n = 3) for the gabapentin-excipient physical mixtures for every time point were 
stored under accelerated conditions of temperature and humidity (50°C and 5% RH) and 
analyzed for the concentrations of gabapentin and lactam using a validated HPLC analytical 
method across 624 h. 
 
The expanded kinetic model for the solid-state degradation of gabapentin as derived in chapter 4  
was applied to the generated data.
1
  The Runge-Kutta 4
th
 order numerical approximation method 
was used to solve the series of differential equations defining the kinetic model.
1
The data 
collected was parameterized by non-linear regression using the Solver function (Excel
®
 2010). 
The initial values for the parameters were the optimized parameter estimates obtained after 
parameterizing the stability data in chapter 3.  
 
The parameters expected to change on compaction and with the presence of excipients included, 
gaba0
*
, due to increased concentration of the reactive gabapentin molecules on exposure to 
mechanical stress, and the rate constant k4 (part of k2
*
), due to the greater contact area between 
gabapentin and excipients. The possible effect of excipient moisture in stabilizing the 
degradation of gabapentin could result in alteration in the value of k3. Hence, gaba0
*
, k2
*
, and k3 
were optimized, followed by the optimization of k1. The values for k3 and k1 were constrained to 
be greater than 10
-8
 to obtain non-zero estimates for the parameters.   
 
The nature of the differential equation for lactam formation, as shown in Equation 36, 
demonstrates mathematical links between k2
*
 and gaba0
*
. We have not attempted to separate their 
effects in compacted samples. We have therefore compared the initial rate for lactam formation 
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represented by k2
*
gaba0
*
 to determine the effect of compaction and the presence of excipients on 
the degradation of gabapentin. 
 
5.3. Results and Discussion 
Lactam formation results for compacted mixtures can be seen in Figure 38. The results 
demonstrate accelerated lactam formation in compacted physical mixtures of gabapentin with 
excipients relative to gabapentin compacted by itself. Application of the expanded kinetic model 
to the data resulted in good fit (indicated by dashed line in Figure 38) between the model-
predicted data and the observed data points with low sum of square error (SSE <0.005) values 
across the different gabapentin-excipient mixtures. 
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Figure 38: Effect of compaction and the presence of excipients on the solid-state 
degradation of gabapentin. Dashed lines indicate model-predicted data. The measured 
lactam concentration is an average of three replicates in gabapentin compacts and 
gabapentin-excipient compacts, and the error bars represent a 95% confidence interval.  
 
The effect of compaction was especially prominant when comparing the slope of the initial 
lactam formation for compacted gabapentin with uncompacted gabapentin in Figure 39.  
The value of k2
*
gaba0
*
, which represents the initial rate of lactam formation, was found to be 
approximately 90% higher in the case of compacted gabapentin in the absence of any excipients 
relative to uncompacted gabapentin.  
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Figure 39: Effect of compaction on gabapentin’s degradation. The data points represent 
the concentration of lactam % mole over time (h) in gabapentin compacts (n = 3) and 
gabapentin uncompacted (n = 3). The error bars represent a 95% confidence interval. 
 
In the case of compacts of physical mixtures of gabapentin and excipients, the accelerated effect 
of lactam formation is a combined effect of compaction conditions and the catalytic effect of 
excipients. Hence, to understand the effect of compaction, the percent increase in the initial rate 
of lactam formation between the gabapentin physical mixtures and their compacts was compared 
as seen in Figure 40. 
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Figure 40: Comparison of the initial lactamization rate (k2
*
gaba0
*
) between the gabapentin-
excipient physical mixtures and compacts. The arrows indicate the percent increase in the 
values of the initial lactamization rate in the case of the compacts of the physical mixtures 
relative to the value of the initial lactamization rate for physical mixtures.  
 
The initial rate of lactam formation (k2
*
gaba0
*
) increased substantially (68%) in the case of 
compacts of gabapentin with Emcompress
®
 and HPMC relative to the value of k2
*
gaba0
*
 in their 
physical mixtures. This effect can also be observed as an increase in the initial slope in the 
lactam formation profiles for mixtures and compacts of gabapentin with excipients in Figure 41 
and Figure 42. Compaction is likely to increase the contact area between gabapentin and the 
excipient particle, accelerating lactam formation by affecting the value of k2
*
. It is important to 
remember that the rate constant k2
*
 incorporates rate constant k4, which is catalyzed by the 
concentration of molecules on the surface of the excipient particle in contact with gabapentin. On 
the other hand, compaction pressure is also likely to increase the concentration of reactive 
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disordered molecules (gaba0
*
) of gabapentin, thus accelerating the initial rate of lactam 
formation.  
 
Figure 41: Effect of compaction on gabapentin’s degradation in the presence of 
Emcompress
®
. The legends represent lactam concentration (%mole) over time in the case 
of physical mixtures and compacts of gabapentin and Emcompress
®
. The error bars 
represent a 95% confidence interval (n = 3). 
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Figure 42: Effect of compaction on gabapentin’s degradation in the presence of HPMC. 
The legends represent lactam concentration (%mole) over time in the case of the physical 
mixtures and compacts of gabapentin and HPMC. The error bars represent a 95% 
confidence interval (n = 3). 
 
It was hypothesized that yield pressure would influence the degradation kinetics of gabapentin. 
This was expected, due to the possible impact of this material property on the extent of 
gabapentin’s fragmentation, increasing the area of contact between gabapentin and excipient 
particles. To understand the effect of yield pressure, a plot of yield pressure for the physical 
mixtures and initial rate of lactam formation is shown in Figure 43.  
 
It was observed that gabapentin-excipient physical mixtures with higher yield pressure  
(>200 MPa), which deform predominantly via brittle fracture, were responsible for a greater 
increase in the rate of initial lactam formation relative to other excipients in the study. Along 
with the materials deforming by brittle fragmentation, the physical mixture of gabapentin and 
HPMC undergoing plastic deformation and with a low yield pressure value (<75 MPa) was also 
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seen to be impacting the initial rate of lactam formation. Hence, the yield pressure of the 
excipients can be considered one of the critical factors that need to be further explored.  
 
 
Figure 43: A plot suggesting the relationship between the initial lactam formation rate and 
the yield pressure of gabapentin-excipient physical mixtures. 
 
Compaction of gabapentin with talc demonstrated no substantial increase in the initial rate of 
lactam formation relative to their physical mixtures as seen in Figure 44. When comparing the 
value of k2
*
gaba0
*
 for the compacts and the physical mixture of gabapentin with talc, a 28% 
increase was observed. The increase in the value of k2
*
gaba0
*
 was relatively lower than that 
observed in the case of the gabapentin-Emcompress
®
 mixture and compacts with a similar 
deformation mechanism. This observation was thought to be due to the finer size (~3 um) of talc 
particles and their tendency to coat the surface of gabapentin in the physical mixture (Figure 44 
(inset)). The coating of talc on the surface of gabapentin is thought to result in a greater level of 
initial contact between the two materials. The contact area between gabapentin and talc was 
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thought to not increase substantially on compaction. However, it is important to point out that the 
initial data points in the degradation profiles for the gabapentin and talc mixtures and the 
compacts have less number of data points to make a conclusive statement. Collecting more data 
points across the initial degradation profile will be important to better support our conclusion.  
 
Figure 44: Effect of compaction on gabapentin’s degradation in the presence of talc. The 
legends represent lactam concentration (% mole) over time in physical mixtures and 
compacts of gabapentin and talc. The trend lines across the data points rationalize the 
slight increase in the initial slope for lactam formation. The error bars represent a 95% 
confidence interval (n = 3). The inset picture shows a morphological representation of 
gabapentin particles coated by talc particles in their physical mixture. 
 
 
The excipient that did not show a substantial increase in lactam formation upon compaction with 
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findings strongly suggest that moisture stabilizes processed gabapentin by healing the disordered 
molecules. Hence, we cannot rule out the effect of the moisture contained in starch to be 
stabilizing the degradation of gabapentin on compaction. 
   
 
Figure 45: Effect of compaction on gabapentin’s degradation in the presence of starch. The 
legends represent lactam concentration (% mole) over time in the case of physical mixtures 
and compacts of gabapentin and starch. The error bars represent a 95% confidence 
interval (n = 3). 
 
To understand if the moisture contained within the excipients could be one of the factors 
affecting gabapentin’s degradation, k2
*
gaba0
*
 and the moisture content (% w/w) of the excipients 
were plotted as in Figure 46. The results showed a potential connection between the rate of initial 
lactam formation and the moisture content of the excipients.  
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Figure 46: A relationship plot of the initial rate for lactam formation and moisture content 
of the excipients. A possible stabilization effect of excipient moisture on lactam formation is 
suggested. 
 
Another excipient that did not show a significant increase in lactam formation on compacting 
with gabapentin was HPC, as seen in Figure 47. The increase in the rate of initial lactam 
formation of the gabapentin-HPC compact was lower relative to the increase in the rate of initial 
lactam formation for the gabapentin-HPMC compact. This was in spite of the moisture content 
and deformation properties of HPC and HPMC being similar. Interestingly, as seen in Figure 48, 
the gabapentin compact with HPC demonstrated the lowest porosity value (0.06) of all 
gabapentin-excipient compacts. HPC was also one of the excipients with higher moisture 
content. Lower porosity of the compact could suggest greater contact area between gabapentin 
and HPC. On the other hand, the higher moisture content of HPC in the compact with high solid 
fraction could potentially stabilize gabapentin by creating a microenvironment with high relative 
humidity within the compact. Hence, understanding the effect of HPC on gabapentin’s 
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degradation on compaction will require further studies that isolate the effects of compact 
porosity, excipient moisture, and excipient yield pressure. 
 
Figure 47: Effect of compaction on gabapentin’s degradation in the presence of HPC. The 
legends represent lactam concentration (% mole) over time in the case of physical mixtures 
and compacts of gabapentin and HPC. The error bars represent a 95% confidence interval 
(n = 3). 
 
 
Figure 48: Comparative plot for porosity of the compacts of gabapentin with excipients. 
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The energy utilized in compact preparation was hypothesized to affect the rate of initial lactam 
formation. Results indicated no substantial effect from this factor, as observed in Figure 49. 
However, it is difficult to make any conclusive statement since a number of other confounding 
factors could be responsible for the observed results.    
 
It is important to note that the data collected from this study is preliminary and only identifies 
potential factors that could be playing a role in gabapentin’s degradation on compaction. Future 
studies can be designed to better quantify the relationship between lactam formation rate and 
these factors. 
 
 
Figure 49: A relationship plot for the initial rate of lactam formation and the work of 
compression for compacts of gabapentin with excipients. Data indicates poor correlation 
between the two factors. 
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The results did not show any substantial effect from the processing conditions and the presence 
of excipients on the rate constants k1 and k3. No substantial difference in the magnitude of k3 was 
observed between the physical mixtures and the compacts of gabapentin with excipients, as seen 
in Figure 50. 
 
Figure 50: Effect of excipients on the rate constant k3 in gabapentin’s degradation kinetics 
 
5.4. Conclusion 
Compaction pressure accelerated the initial rate of lactam formation in pure gabapentin compacts 
relative to unprocessed gabapentin. This effect was potentially due to an increase in the 
concentration of reactive molecules available for lactamization. Accelerated lactam formation in 
compacts of gabapentin with excipients was expected to be a result of the increased 
concentration of reactive gabapentin (gaba0
*
) and the increased catalytic effect of excipients due 
to more intimate contact between gabapentin and the excipients. Rate constants k1 and k3 were 
not impacted substantially by the application of compaction pressure or by the powder properties 
of excipients. 
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The above preliminary study suggested a possible effect of yield pressure, moisture content, and 
particle size of the excipient, and compact porosity on the initial rate for lactam formation in 
gabapentin-excipient compacts. Further studies are needed to understand the impact of the 
identified factors on gabapentin’s degradation and to quantify the relationship between the 
factors and the initial rate of lactam formation. 
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Chapter 6 
Conclusion 
The objective of the presented research was to understand the role of excipients and compaction 
conditions on the solid-state degradation of gabapentin. It was hypothesized, that 
physicochemical properties (such as specific surface area, molecular weight, particle size, 
particle shape and, acidic or basic strength) of the excipients will accelerate the solid-state 
degradation of gabapentin, increasing the rate constant (k2) for lactam formation. The 
degradation kinetics, predominantly the initial rate for lactam formation will be further 
accelerated by compaction of the gabapentin-excipient physical mixtures. 
  
To test this hypothesis, five specific aims were designed. The first specific aim was to develop 
and validate (ICH Q2A guidelines) a robust analytical method for accurate quantitation of 
gabapentin and lactam. The results for studies associated with this aim are discussed in chapter 2. 
The second specific aim of the project as discussed in chapter 3 was to provide evidence for the 
effect of excipients on the solid-state degradation of gabapentin in the absence of any processing 
conditions. The third specific aim of the project as discussed in chapter 4, was to understand the 
effect of excipient concentration and its particle size on the degradation of gabapentin in solid-
state. This aim also included expansion of the existing kinetic model to account for the effect of 
excipient properties. The fourth specific aim, also discussed in chapter 4, was to develop a 
mechanistic relationship between the physical properties of the excipient (such as shape, size, 
density, molecular cross sectional area, molecular weight, and surface area) with the rate 
constant for lactam formation. The relationship has the potential to estimate the effect of 
excipients based on their physical and chemical properties. The final specific aim of the project 
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as discussed in chapter 5 was to understand the role of compaction conditions and powder 
properties of excipients on the solid-state degradation of gabapentin.  
 
The results in Chapter 2 highlighted the successful validation of an isocratic HPLC-UV 
analytical method, as per the ICH Q2A guidelines. The results confirmed the purity of the 
procured gabapentin sample to be comparable to that of the acquired USP reference standard. 
Inter-day and intra-day measurements, demonstrated the analytical method to be accurate, 
precise and robust. The method demonstrated specificity with respect to the elution of gabapentin 
and lactam in the presence of excipients. The results, confirmed absence of interference either 
from the filter membrane or from the excipients for extraction of lactam and gabapentin in 
solution. Lactam was found to be stable both in the mobile phase and in the sample solvent, for 
the entire duration of the study. On the other hand, the degradation rate of gabapentin in solution 
was observed to be too low to interfere with the results of solid-state degradation studies.   
 
Results from chapter three provided strong evidence that excipients accelerate the degradation of 
unprocessed gabapentin to lactam in solid-state. Application of the existing kinetic model 
highlighted that the excipients significantly (p>0.05) affect the initial rate of lactam formation. 
This initial rate is described by rate constants k2 and the concentration of reactive gabapentin 
molecules (gaba0
*
). The results partly proved the hypothesis that “properties of the excipients 
will accelerate the rate constant (k2) for spontaneous lactam formation”. Fixing a lower value of 
gaba0
*
 and a value of k2, as established previously in the literature, successfully predicted the 
gabapentin degradation profile with a high R
2
 value (>0.97). However, the same lower value of 
gaba0
*
 was unable to fit the data for the gabapentin-excipient binary mixture, which had the 
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highest lactam formation rate. The higher estimated value for gaba0
*
 in most cases of gabapentin-
excipient binary mixtures was the result of high lactam formation, measured in the initial time 
period of the stability study. As per the model assumption, the initial lactam formation is 
predominantly due to the spontaneous conversion of gaba0
*
. Thus, to observe the high initial 
lactam content as seen in the results from chapter 3, a greater concentration of gaba0
*
 will have to 
be present as indicated by the model predicted estimate. The lowest value of gaba0
*
 that provided 
a good fit (R
2
<0.99) was 3% mole. Fixing the value of gaba0
*
 lower than 3% mole resulted in a 
poor model fit to the data. Interestingly, higher value of gaba0
*
 provided a good fit for the 
gabapentin data with an R
2
 value of (>0.97) and sum of square error value of 0.0005. The fit was 
comparable (similar values for R
2
 and SSE) to that obtained for the gabapentin data with lower 
value of gaba0
*
. 
 
The lower estimated value of gaba0
*
 in previously established studies is entirely based on the 
data generated after milling gabapentin in the absence of excipients. Thus, greater initial lactam 
formation is attributed to the higher concentration of gaba0
* 
on milling. However, after 
accounting for the catalytic effect of the excipients on the rate constant k2, the value of gaba0
*
 
was estimated to be 3% mole for unprocessed gabapentin present in all the binary mixtures.  The 
concentration of reactive gabapentin molecules was defined as the sum of all surface molecules 
and other disordered molecules in the crystal. The concentration of reactive molecules was 
unexpectedly higher and hence will require further investigation.  
 
The rate constant k2 showed a significant (p<0.05) increase in the presence of excipients relative 
to its value for gabapentin. Amongst the excipients tested, inorganic excipients (Tri-Tab
®
,  
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A-Tab
®
, Talc and Emcompress
®
) were seen to impact the degradation kinetics of gabapentin far 
more than polymers (HPMC, HPC and starch). Rate constants k1 and k3 were relatively less 
affected in the presence of most excipients. However, in physical mixtures of gabapentin with 
Tri-Tab
®
 and A-Tab
® 
the value of k1 and k3 was estimated to be significantly lower than that of 
gabapentin by itself. This effect is likely due to the higher magnitude (x100) of k2 relative to k1 
and k3, resulting in masking the branching and termination phase in the solid-state degradation 
profile. The branching phase described by rate constants k1 and k3, is observed clearly in the case 
of the degradation profiles for gabapentin, starch and Mono-Tab, which have lower values of k2. 
 
Concentration dependent catalytic effect of the excipients was observed in the results from 
chapter 4 where, as the mass of the excipient in the binary mixture with gabapentin increased, 
there was an increase in the lactam content. This concentration dependent catalytic effect of the 
excipients was incorporated into the existing kinetic scheme. The kinetic model was expanded by 
addition of rate constant k4, surface molar concentration of excipients (E) and apparent rate 
constant k2
*
. Apparent rate constant k2
*
, was the sum of catalytic rate constant k4 and 
uncatalyzed rate constant k2.  
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The final set of differential equations to predict lactam formation for the degradation of 
gabapentin in the presence of excipients would be as follows:  
𝐝[𝐠𝐚𝐛𝐚]
𝐝𝐭
= −𝒌𝟏[𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂
∗ + 𝑳] + 𝒌𝟑[𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂
∗]       Equation 44      
𝐝[[𝐠𝐚𝐛𝐚∗]
𝐝𝐭
=  𝒌𝟏[𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂
∗ + 𝑳] − 𝒌𝟑[𝒈𝒂𝒃𝒂][𝒈𝒂𝒃𝒂
∗] − 𝒌𝟐[𝒈𝒂𝒃𝒂
∗] −
                     𝒌𝟒 [𝒈𝒂𝒃𝒂
∗][𝐄]  
Equation 45                                            
𝐝[𝐋]
𝐝𝐭
= 𝐠𝐚𝐛𝐚∗ 𝒌𝟐
∗       Equation 46         
(𝐤𝟐 + 𝐤𝟒𝐄) = 𝒌𝟐
∗       Equation 47        
 
In the above equations:  
k1 (mol
-1
h
-1
) is the autocatalytic rate constant 
k2 (h
-1
) is the uncatalyzed rate constant for spontaneous lactam formation 
k3 (mol
-1
h
-1
) is the termination rate constant catalyzed by environmental moisture 
k4 (mol
-1
h
-1
) is the excipients catalyzed rate constant for spontaneous lactam formation 
k2
*
( h
-1
)  is the apparent rate constant for spontaneous lactam formation, which is the sum of both 
the catalyzed and the uncatalyzed rate constant 
gaba (% mole) is the concentration of stable gabapentin molecules  
gaba
*
 (% mole) is the concentration of reactive gabapentin 
 L (% mole) is the lactam concentration  
t (h) is time.  
 
Total molar concentration (E) on the surface of the excipient particle was represented using the 
specific surface area, the molecular cross sectional area and the molecular weight of the 
excipient. Results in chapter 4, also demonstrated an effect of excipient particle size on the rate 
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of lactam formation. Increasing particle size of the excipient molecules demonstrated decrease in 
rate of lactam formation. This finding highlighted the importance of estimating actual surface 
contact between gabapentin and the excipient based on their particle morphology and size. The 
fraction of molar concentration on the excipient surface which is in contact with gabapentin, was 
estimated (based on particle size, true density, the morphology of the excipient and gabapentin), 
by using the Komatsu model.
89
 Results from chapter 4 proved the hypothesis that both the 
physical and the chemical properties of the excipients affect the lactamization kinetics. 
 
The major physical properties of the excipients were measured and incorporated into the 
developed model which helped estimate the rate constant k4 as it is affected by chemical 
properties of the excipients. Estimation of the excipient catalyzed rate constant, indicated greater 
impact of inorganic salts of basic nature (Tri-Tab
®
 (pKa 12.12), A-Tab
®
 (pKa 7.4), Talc (pKa 
9.19) and Emcompress
®
 (pKa 7.4)) relative to inorganic excipients of acidic nature (Mono-Tab 
(pKa 2.12)). Polymers (HPMC, HPC and starch) had a lower impact on the degradation of 
gabapentin relative to the inorganic excipients. However, considering the limited number of 
excipients used, it was difficult to strongly conclude that any particular chemical property was 
impacting degradation kinetics of gabapentin. Further expansion of the excipient library will be 
required to establish relationships between chemical properties of the excipients and the rate 
constants describing the degradation kinetics. 
 
Comparing the initial rate (k2
*
gaba0
*
) of lactam formation between gabapentin-excipient physical 
mixtures and their compacts in Chapter 5, showed that compaction pressure and powder 
properties affected gabapentin’s degradation. Results from the study proved the hypothesis that 
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“The degradation kinetics, predominantly the initial rate of lactam formation will be further 
accelerated by compaction of gabapentin-excipient physical mixtures”. Results indicated 
accelerated initial rate of lactam formation in case of compacted gabapentin. This is 
hypothesized to be due to damage caused to its crystals, which would lead to increased 
concentration of reactive molecules. Results also indicated the potential role of compact porosity, 
yield pressure of physical mixtures, and moisture content of excipient and excipient particle size 
in accelerating lactam formation.  
 
In summary, excipients impacted solid-state degradation of gabapentin. This impact was 
incorporated into the previously established kinetic model. The developed relationship between 
the apparent rate constant for lactam formation and the physical properties of excipients can be 
further explored, as a risk assessment tool. This tool would help predict lactam formation in 
gabapentin formulations over time, with variations in the physical properties of excipients and 
compaction conditions.  
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Appendix 1 
Supporting data Chapter 1 
 
1. Analytical method validation: Specificity (matrix effect) 
 The results confirmed the absence of excipient interaction in the elution of 
gabapentin and lactam. 
 Excipient solutions were analyzed using the HPLC technique, to identify for any 
peaks specific to the excipients, interfering with the elution of either gabapentin 
and/or lactam 
 The concentration of the excipient solution (4mg/ml) was selected based on the 
expected concentration in the solutions of their physical mixtures and compacts 
with gabapentin. 
 
            Figure 51: The chromatogram for HPC at a concentration of 4 mg/ml  
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Figure 52: The chromatogram for HPMC at a concentration of 4 mg/ml 
 
                
 
                
Figure 53: The chromatogram for starch at a concentration of 4 mg/ml 
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Figure 54: The chromatogram for talc at a concentration of 4 mg/ml 
 
 
   
Figure 55: The chromatogram for Emcompress
®
 at a concentration of 4 mg/ml 
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Figure 56: The chromatogram for Tri-Tab
®
 at a concentration of 4 mg/ml 
 
 
Figure 57: The chromatogram for A-Tab
®
 at a concentration of 4 mg/ml 
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Figure 58: The chromatogram for Mono-Tab at a concentration of 4 mg/ml 
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Appendix 2 
Supporting documentation for chapter 4 
Specific surface area measurements 
 Multipoint measurements were performed using nitrogen vapor adsorption data with 
subsequent application of the BET model 
 Material weight:  1.00-1.5 g 
 Samples were outgassed at high temperatures (50-200°C depending on the material) for 
more than 24 h. 
 Single sample of each excipient was analyzed 
 The moles of nitrogen adsorbed at each partial pressure was analyzed using the BET 
equation (Equation 23) 
 Specific surface area was calculated as the quotient of the samples total surface area and 
mass 
 
 
Figure 59: A multi-point BET measurement for Kaolinite reference standard.  
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Figure 60: A multi-point BET measurement for Alumina reference standard.  
 
 
 
 
Figure 61: A multi-point BET measurement for Tri-Tab
®
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Figure 62: A multi-point BET measurement for A-Tab
®
 75-125µm 
 
 
Figure 63: A multi-point BET measurement for A-Tab
®
 125-250µm 
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Figure 64: A multi-point BET measurement for A-Tab
®
 250-500 µm  
 
 
Figure 65: A multi-point BET measurement for Mono-Tab
®
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Figure 66: A multi-point BET measurement for Emcompress
®
  
 
 
           
Figure 67: A multi-point BET measurement for starch  
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Figure 68: A multi-point BET measurement for HPMC 
 
 
Figure 69: A multi-point BET measurement for HPC 
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Figure 70: A multi -point BET measurement for talc 
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Molecular Cross-Sectional area measurements 
 
Computation of molecular cross-sectional area for excipients, 
Step 1: Structures of the excipients were constructed using Chem-Draw
®
 
Step 2: Transformation of 2-D structures to 3-D structures was performed on MOE
® 
 
Step 3: Energy minimization was performed using MMF94X force field in MOE
®
 
Step 4: Bond distances for different molecular orientations of the excipients were measured. Two 
major orientations of the molecules on the surface of the excipient particle were assumed. 
Step 5: Surface for the excipient structure in 3-D was generated. The colors on the surface were 
indicative of H-bonding sites (Pink), hydrophobic sites (Blue), and mild polar sites (green). 
Step 6: The final distances (length and breadth) across the molecular surface for the two 
orientations were measured and the van-del-Waals radii for atoms was added to the measured 
bond lengths 
Step 7: The molecular cross sectional area (𝐴 = 𝜋(length major axis × length minor axis)) 
was calculated assuming an ellipsoidal geometry at the cross section. 
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Figure 71: Computation of molecular cross-sectional area for A-tab
®
 
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the 
molecule. B. Measured dimensions for orientation 2 of the molecule. C.  Surface constructed for 
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The 
surface accounts for the van-der Waals radii of atoms. 
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Figure 72: Computation of molecular cross-sectional area for Emcompress
®
 
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the 
molecule. B. Measured dimensions for orientation 2 of the molecule. C.  Surface constructed for 
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The 
surface accounts for the van-der Waals radii of atoms. 
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Figure 73: Computation of molecular cross-sectional area for HPC 
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the 
molecule. B. Measured dimensions for orientation 2 of the molecule. C.  Surface constructed for 
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The 
surface accounts for the van-der Waals radii of atoms. 
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Figure 74: Computation of molecular cross-sectional area for HPMC 
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the 
molecule. B. Measured dimensions for orientation 2 of the molecule. C.  Surface constructed for 
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The 
surface accounts for the van-der Waals radii of atoms. 
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Figure 75: Computation of molecular cross-sectional area for Mono-Tab 
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the 
molecule. B. Measured dimensions for orientation 2 of the molecule. C.  Surface constructed for 
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The 
surface accounts for the van-der Waals radii of atoms. 
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Figure 76: Computation of molecular cross-sectional area for starch 
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the 
molecule. B. Measured dimensions for orientation 2 of the molecule. C.  Surface constructed for 
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The 
surface accounts for the van-der Waals radii of atoms. 
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Figure 77: Computation of molecular cross-sectional area for talc 
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the 
molecule. B. Measured dimensions for orientation 2 of the molecule. C.  Surface constructed for 
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The 
surface accounts for the van-der Waals radii of atoms. 
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Figure 78: Computation of molecular cross-sectional area for Tri-Tab
®
 
A. Measured dimensions (bond length measuring length and breadth) for Orientation 1 of the 
molecule. B. Measured dimensions for orientation 2 of the molecule. C.  Surface constructed for 
the molecule in orientation 1. D. Surface constructed for the molecule in orientation 2. The 
surface accounts for the van-der Waals radii of atoms. 
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